



Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease

Anna Chiarini¹, Ubaldo Armato^{1*}, Daisong Liu^{1,2} and Ilaria Dal Prà¹

¹ Human Histology and Embryology Unit, University of Verona Medical School, Verona, Italy, ² Proteomics Laboratory, Institute for Burn Research, Third Military Medical University, Chongqing, China

OPEN ACCESS

Edited by:

Enikő Kallay,
Medical University of Vienna, Austria

Reviewed by:

Michio Nomura,
Kyoto University, Japan
Stephen Mark Smith,
Veterans Affairs Palo Alto Health Care
System/Oregon Health & Science
University, USA

*Correspondence:

Ubaldo Armato
uarmato@me.com

Specialty section:

This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology

Received: 25 January 2016

Accepted: 28 March 2016

Published: 26 April 2016

Citation:

Chiarini A, Armato U, Liu D and Dal Prà I (2016) Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease. *Front. Physiol.* 7:134. doi: 10.3389/fphys.2016.00134

In aged subjects, late-onset Alzheimer's disease (LOAD) starts in the lateral entorhinal *allocortex* where a failure of clearance mechanisms triggers an accumulation of neurotoxic amyloid- β_{42} oligomers ($A\beta_{42}$ -os). In neurons and astrocytes, $A\beta_{42}$ -os enhance the transcription of $A\beta$ precursor protein (APP) and β -secretase/BACE1 genes. Thus, by acting together with γ -secretase, the surpluses of APP and BACE1 amplify the endogenous production of $A\beta_{42}$ -os which pile up, damage mitochondria, and are oversecreted. At the plasmalemma, exogenous $A\beta_{42}$ -os bind neurons' and astrocytes' calcium-sensing receptors (CaSRs) activating a set of intracellular signaling pathways which upkeep $A\beta_{42}$ -os intracellular accumulation and oversecretion by hindering $A\beta_{42}$ -os proteolysis. In addition, $A\beta_{42}$ -os accumulating in the extracellular milieu spread and reach mounting numbers of adjacent and remoter teams of neurons and astrocytes which in turn are recruited, again via $A\beta_{42}$ -os•CaSR-governed mechanisms, to produce and release additional $A\beta_{42}$ -os amounts. This relentless self-sustaining mechanism drives AD progression toward upper cortical areas. Later on accumulating $A\beta_{42}$ -os elicit the advent of hyperphosphorylated (p)-Tau oligomers which acting together with $A\beta_{42}$ -os and other glial neurotoxins cooperatively destroy wider and wider cognition-related cortical areas. In parallel, $A\beta_{42}$ -os•CaSR signals also elicit an excess production and secretion of nitric oxide and vascular endothelial growth factor-A from astrocytes, of $A\beta_{42}$ -os and myelin basic protein from oligodendrocytes, and of proinflammatory cytokines, nitric oxide and (likely) $A\beta_{42}$ -os from microglia. Activated astrocytes and microglia survive the toxic onslaught, whereas neurons and oligodendrocytes increasingly die. However, we have shown that highly selective allosteric CaSR antagonists (calcilytics), like NPS 2143 and NPS 89626, efficiently suppress all the neurotoxic effects $A\beta_{42}$ -os•CaSR signaling drives in cultured cortical untransformed human neurons and astrocytes. In fact, calcilytics increase $A\beta_{42}$ proteolysis and discontinue the oversecretion of $A\beta_{42}$ -os, nitric oxide, and vascular endothelial growth factor-A from both astrocytes and neurons. Seemingly, calcilytics would also benefit the other types of glial cells and cerebrovascular cells otherwise damaged by the effects of $A\beta_{42}$ -os•CaSR signaling. Thus, given at amnesic minor cognitive impairment (aMCI) or initial symptomatic stages, calcilytics could prevent or terminate the propagation of LOAD neuropathology and preserve human neurons' viability and hence patients' cognitive abilities.

Keywords: calcium-sensing receptor, calcilytic, human, neurons, astrocytes, oligodendrocytes, microglia, Alzheimer's disease

ALZHEIMER'S DISEASE (AD): AN INTRODUCTION


During the last decades, human lifespan has lengthened due to progress in medical knowledge and improvements in nutrition and hygiene. Unfortunately, this has been paralleled with an increased prevalence of age-related ailments, including neurodegenerative diseases, which have adversely impacted the quality of life. The *sporadic* or *late-onset Alzheimer's disease* (LOAD) is the most prevalent of these dementias striking ~60 million people worldwide, half of which in the European Union and United States (Alzheimer's Association, 2012). AD has a lengthy (20–45 years) asymptomatic or preclinical phase, followed by an amnesic minor cognitive impairment phase (aMCI: 2–6 years) that in most subjects evolves into the terminal fully symptomatic phase (6–12 years; Selkoe, 2008a,b; Sperling et al., 2011). AD's less frequent (1–5% of all cases) *early onset* (around 60 years) *familial* (autosomal dominant) form (EOFAD) is caused by mutations in genes encoding the amyloid precursor protein (APP) or presenilin 1 (PSEN1) or presenilin 2 (PSEN2). These mutations trigger excess production and secretion of amyloid- β peptides (A β s) and formation of toxic oligomers (A β -os) and polymers (fibrils). Most EOFAD cases result from PSEN1 mutations, those from APP and PSEN2 mutations being rarer (Selkoe, 2008a,b). The dramatic effects elicited by the A β s excess due to such mutations have inspired the “*amyloid cascade hypothesis*” of AD which posits that A β -os precede the manifestation of toxic hyperphosphorylated (p)-Tau proteins and neurofibrillary tangles (NFTs) (Hardy and Selkoe, 2002; Selkoe, 2008a,b). Conversely, the “*Tau first hypothesis*” of AD posits that just the opposite happens (Attems et al., 2012; Braak and Del Tredici, 2013; Braak et al., 2013). An extended post-mortem survey revealed that AD cognitive decline is linked to both A β s and p-Taues build-ups (Murray et al., 2015). However, Choi et al. (2014) provided evidence that, in a 3D human neural stem cells (NSCs) culture system, the accumulation of A β -os precedes any p-Tau/NFTs materialization thereby validating the “*amyloid cascade hypothesis*.” Bilousova et al. (2016) confirmed that this A β -os \Rightarrow p-Tau sequence occurs also in advanced AD stages,

strengthening the view that an anti-amyloid therapy must be started in advance of the tauopathy onset.

Albeit clinically both EOFAD and LOAD present with a similarly increasing memory failure, at variance with EOFAD's known mutations, LOAD's etiologic factors are manifold and controversial. The slow concurrence of several age-related metabolic and vascular defects presumably triggers LOAD by hindering the mechanisms which effect the brain's physiological clearance of A β s (Domert et al., 2014). Two genetic factors only are known to aid LOAD's onset and progression, i.e., the heterozygous or homozygous presence of apolipoprotein E (APOE) ϵ 4 allele(s) and TREM-2 mutations, especially the R47H one (Ising et al., 2015). AD's neuropathological hallmarks are accumulations of A β s as senile plaques in the neuropil, intra-neuronal build-ups of p-Taues as insoluble NFTs, a chronic diffuse neuroinflammation, and the progressive death of neurons and oligodendrocytes. Such characteristics are detectable and more intense in wide cortical and subcortical regions starting at least 15 years ahead of EOFAD's clinical onset (Braak and Braak, 1991a; Armstrong, 2011; Benzinger et al., 2013). Conversely, LOAD starts from neuronal *foci* in the layer II of the lateral entorhinal cortex (LEC) of the middle temporal lobe in humans and AD-model transgenic (Tg) mice (Khan et al., 2014). Synaptically disconnected and decreasing neurons stuffed up with A β s and NFTs appear first in the LEC *allocortex* and *subiculum/CA1* areas (Braak and Braak, 1991a; Gómez-Isla et al., 1996; Khan et al., 2014) and later spread slowly to the parietal lobes and other cognition-related cortical areas of human AD brains (reviewed in Dal Prà et al., 2015a; **Figure 1A**). Remarkably, LEC is the portal through which the perforant pathway conveys multimodal data illustrating events of the outside world to the memory-recording hippocampus (Klemm, 2014). Next, the hippocampal *allocortex* and prefrontal *neocortex* mutually interact through the LEC to consolidate integrated memories (Klemm, 2014). These bidirectional exchanges are compromised by the ravages LEC suffers at the aMCI stage of LOAD. Hence, the first clinical harbingers of LOAD are worsening failures of the declarative memory.

The present lack of an anti-AD beneficial therapy is due to several concurrent causes: (i) LOAD's etiology is still hotly debated; (ii) EOFAD and LOAD are diseases typical of the human central nervous system (CNS) whose features can be only partially modeled in animals because of the huge differences in brain structures and cellular functions. The significant losses of hippocampal and neocortical neurons while the astrocytes survive are emblematic of human AD. Conversely, in most Tg rodents AD-models neurons are spared whereas astrocytes undergo an earlier cytotoxic injury and death. That's why any drug reportedly “successful” in AD-model animals has failed the test of clinical trials (reviewed in Han et al., 2015); and (iii) most previous clinical trials of candidate anti-AD drugs recruited patients already at the symptomatic stage of EOFAD or LOAD, *viz.* their cognitive cortical areas had already undergone irretrievable damage (Cummings et al., 2014). These failures have taught at a high cost that any anti-LOAD therapy must be started as early as possible, i.e., at the aMCI stage or just a little later for the time being (or earlier when it will be feasible).

Abbreviations: α 7-nAChR(s), α 7-nicotinic acetylcholine receptor(s); AD, Alzheimer's disease; (a)MCI, (amnesic) minor cognitive impairment; ANT(s), astrocyte-neuron team(s); APOE, apolipoprotein E; APP, A β precursor protein; A β (s), amyloid- β peptide(s); A β ₄₂-os, amyloid- β ₄₂ oligomers; β -S, BACE1/ β S, β -secretase; CAA, cerebral amyloid angiopathy; CaSR, calcium-sensing receptor; CKD, chronic kidney disease; EOFAD, early onset familial (autosomal dominant) AD; fMRI, functional Magnetic Resonance Imaging; GABA, γ -amino butyric acid; γ -S, γ -secretase; GFAP, glial fibrillary acidic protein; GPCRs, G-protein-coupled receptors; LDL, low density lipoprotein; LEC, lateral entorhinal *allocortex*; LOAD, late-onset (sporadic) AD; LRP1, LDL receptor-related protein 1; LTP, long-term potentiation; MBP, myelin basic protein; NAHAs, normofunctioning adult human astrocytes (from cerebral cortex); n.d., not determined; NFTs, neurofibrillary tangles; NMDA, N-methyl-D-aspartate; NO, nitric oxide; NSCs, neural stem cells; NVU(s), neurovascular unit(s); p75^{NTR}, p75 neurotrophin (receptor); PAR-4, prostate apoptosis response-4; pE, pyroglutamate; PET, positron emission tomography; PKA, protein kinase A; PSEN1/2, presenilin 1/2; (p)-Tau-os, hyperphosphorylated Tau protein oligomers; (p)-Tau(es), hyperphosphorylated Tau protein(s); PTH, parathyroid hormone; TF(s), transcription factor(s); Tg, transgenic; VEGF-A, vascular endothelial growth factor A; VFT, Venus Fly Trap; WT, wild-type; 7TM, seven transmembrane α -helices region.



Hitherto, no specific marker of the preclinical stage of LOAD has been validated. However, changes in cerebrospinal fluid total Tau protein, p-Tau, and $A\beta_{42}$ levels, novel techniques of high-resolution functional Magnetic Resonance Imaging (fMRI), and genetic risk profiling show the potential of a future early diagnosis (Nordberg, 2015).

$A\beta$ s AND AD NEUROPATHOLOGY

In healthy human brains, neurons steadily produce physiologically low amounts (~ 200 pM) of harmless monomeric $A\beta_{42}$ s and release them during synaptic activity (Puzzo et al., 2008, 2011; Abramov et al., 2009; Garcia-Osta and Alberini, 2009). $A\beta$ s are synthesized via sequential enzymatic cleaving of the transmembrane $A\beta$ precursor protein (APP) by BACE1/ β -secretase (β -S) and γ -secretase (γ -S) (Takami and Funamoto, 2012). According to the "classical" view, only neurons express β -S in normal brains, whereas astrocytes do it only when hit by stressful insults (Kimura et al., 2005; Lee et al., 2014). However, proliferatively quiescent untreated normofunctioning adult human astrocytes (NAHAs) isolated from surgical leftovers of the temporal lobe cortex and cultured *in vitro* exhibit, at variance with rodent astrocytes, low basal levels of β -S and γ -S activity and hence produce and release trivial amounts of $A\beta_{42}$ and $A\beta_{40}$ (Dal Prà et al., 2011; Armato et al., 2013a).

Normally, the production of $A\beta_{40}$ prevails (90%) on that of $A\beta_{42}$ (10%), but in AD the $A\beta_{42}/A\beta_{40}$ ratio shifts in favor of $A\beta_{42}$ (Masters and Selkoe, 2012). $A\beta_{42}$'s two C-terminal

hydrophobic amino acids, Ala and Ile, cause its greater proclivity to form aggregates and resist proteolysis with respect to $A\beta_{40}$ (Kim and Hect, 2005; Masters and Selkoe, 2012). At safe pM concentrations $A\beta_{42}$ monomers play important trophic functions by: (a) inducing an enhanced expression of proteins related to insulin-like growth factor (IGF) function or transcription factor (TF) regulation (IGFBP3/5, and Lim only domain protein 4, respectively); (b) favoring adult neurogenesis in the subgranular zone of dentate gyrus; (c) modulating synaptic plasticity, long-term potentiation (LTP), and memories recording in the hippocampus; (d) sealing blood vessels to preserve blood-brain barrier (BBB) integrity; and (e) fine-tuning Ca^{2+} homeostasis by binding $\alpha 7$ -nicotinic acetylcholine receptors ($\alpha 7$ -nAChRs) and enhancing *intracellular* Ca^{2+} signals without triggering *intercellular* Ca^{2+} waves in astrocytes. Thus, $A\beta_{42}$ monomers assist in the mutual modulation of neuron-astrocyte signals promoting long-term potentiation (LTP) and memory storing (Plant et al., 2003; Koudinov and Berezov, 2004; Puzzo et al., 2008, 2011; Garcia-Osta and Alberini, 2009; Morley et al., 2010; Cárdenas-Aguayo et al., 2014; Lee et al., 2014; Storck et al., 2016). $A\beta_{42}$ s are kept at physiological pM levels via the activity of proteases like insulin-degrading enzyme, neprilysin, angiotensin-converting enzyme, endothelin-converting enzyme, and the ubiquitin-proteasome system (López Salon et al., 2003; Wang et al., 2006). Additional $A\beta$ -disposing mechanisms are microglial phagocytosis, and dumping into the circulating blood through the $\alpha 2$ -macroglobulin receptor/low density lipoprotein receptor-related protein 1 (LRP1) (Storck et al., 2016).

Such monomeric A β -clearing mechanisms become inadequate when mutations of *APP* or *PSEN1* or *PSEN2* genes cause an overproduction of A β s as in EOFAD or when they significantly decline with age and fail in LOAD (Tarasoff-Conway et al., 2015). The resulting accumulation of A β_{42} s triggers the assembling of A β_{42} monomers into an assortment of toxic A β_{42} oligomers (A β_{42} -os) of growing sizes eventually forming A β fibrils (Braak and Braak, 1991b; Mawuenyega et al., 2010; Masters and Selkoe, 2012; Lesnè et al., 2013). In addition, the generation of long fatty acid-derived oligomers (LFA-os) via a prion-like mechanism (Kumar and Walter, 2011; Kumar A. et al., 2012), the increasing presence of the A β_{43} isoform (Sandebring et al., 2013), and the A β -phosphorylating activity of membrane-bound or extracellular protein kinase A (Kumar and Walter, 2011; Kumar S. et al., 2012) accelerate the rate of A β -os assembly, reduce their proteolytic or microglia-mediated clearance, and step up their neurotoxicity. Another toxic species is pyroglutamate (pE)-A β_{3-42} , which amounts to ~20% of the total A β s in AD brains, but is missing among the A β s extracted from aged yet cognitively normal brains (Gunn et al., 2010; Jawhar et al., 2011). In AD-developing human brains, pE-A β_{3-42} engenders pure or mixed (with other A β s) highly toxic oligomers, the amount of which tightly correlates with the actual rate of cognitive decline (Morawski et al., 2014). Additionally, the N-truncated A β_{4-42} also abounds in AD brains and spawns stable A β_{4-42} -os which are as neurotoxic as A β_{1-42} -os and pE-A β_{3-42} -os *in vitro* and in the mouse Tg4-42 transgenic line (Bouter et al., 2013). Moreover, interactions with cell membranes increase the aggregation rate of A β_{42} -os and produce amyloid pores and Ca $^{2+}$ -permeable channels resulting in an intracellular Ca $^{2+}$ dyshomeostasis promoting the neurodegeneration (Mattson, 2007; Kawahara, 2010; Zhao et al., 2012; Berridge, 2014). However, being pathologically bound and activated by A β_{42} -os, the calcium-sensing receptor (CaSR) expressed by all types of neural cells is also involved in AD development via mechanisms implicating much more than Ca $^{2+}$ influxes.

INTERACTIONS BETWEEN NEURONS AND ASTROCYTES IN LOAD

Neurons and astrocytes derive from embryonic radial glia acting as neural stem cells (NSCs) during development (Bonfanti and Peretto, 2007). Accumulating evidence has shown that human cortical astrocytes remarkably differ from their rodent counterparts. They are bulkier, own 10-fold more numerous primary processes, include the entirely new cortical polar and interlaminar subtypes, exhibit a different transcriptome as assessed by genome-wide unbiased comparisons, govern much broader synaptic domains, and perform more intense and complex metabolic tasks, e.g., faster Ca $^{2+}$ waves propagation, than rodents' counterparts (Oberheim et al., 2006, 2009, 2012; Sherwood et al., 2006; Tsai et al., 2012; Zhang et al., 2016). Astrocytes' evolutionary changes have affected both human brain physiology and neuropathology, including AD and other neurodegenerative disorders. The increased learning capacity

and activity-dependent plasticity of mouse brains engrafted with human astrocytes confirms this view (Han et al., 2013). Human brain evolutive changes prevent AD-model animals from fully emulating human LOAD. This hampers any successful translation of pharmacological results reaped from AD-model animals to human clinical settings (Cummings et al., 2014; Han et al., 2015). Astrocytes' roles in AD progression deserve a careful consideration. Such cells are more numerous (from 1.7- to 2.2-fold at least) than neurons, form gap junction-connected networks, partake in the assembly of tripartite synapses, and tightly nestle and chemically insulate neurons with which physiologically trade several indispensable compounds (Ullian et al., 2001). Each "master" astrocyte functionally integrates with up to a 30-odd "client" neurons forming *astrocyte-neuron teams* (ANTs; reviewed in Araque and Navarrete, 2010; Giaume et al., 2010; Halassa and Haydon, 2010). Neighboring ANTs are reciprocally connected via gap junctions astrocytes' processes bear. Other astrocytes processes get in touch by means of their end-feet with the walls of cerebral micro vessels forming physiologically integrated *neurovascular units* (NVUs) (Figure 1B; reviewed in Dal Prà et al., 2014b; Nelson et al., 2016). Physiologically, the synapses of ANTs "client" neurons are induced and stabilized by the shrouding end-feet of their "master" astrocytes. Moreover, the synapses pertaining to a single neuron can also be enveloped by the processes end-feet of astrocytes pertaining to neighboring ANTs. Importantly, the astrocytes of connected ANTs promote or reduce the release of neurotransmitters into the synapses they wrap thus modulating neural transmission by (a) sweeping up spilled over glutamate and K $^{+}$; (b) releasing "gliotransmitters" like glutamate, ATP, D-serine, γ -amino butyric acid (GABA), and taurine; and (c) letting out or taking up, respectively, Ca $^{2+}$ ions during their Ca $^{2+}$ waves (Antanitus, 1998; Bushong et al., 2002; Kettenmann and Ransom, 2013; Gundersen et al., 2015). The term *infotropism* defines the control of neurotransmitter release and hence of synaptic function by the astrocytes (Antanitus, 1998). Astrocytes' activation is coupled with intracellular Ca $^{2+}$ transients and intercellular gap-junction-mediated Ca $^{2+}$ waves and triggers both locally and remotely the secretion of gliotransmitters modulating astrocyte-astrocyte and astrocyte-neuron signaling (Lee et al., 2014). Moreover, astrocytes express receptors for other neurotransmitters—like purines, GABA, and N-methyl-D-aspartate (NMDA)—and control extracellular ion levels (e.g., K $^{+}$), pH, and water volume (reviewed in Kettenmann and Ransom, 2013). Because of these distinctive properties, human astrocytes likely play a role as neuronal partners in learning, memory, and cognition—all functions progressively lost in AD.

In AD, extracellularly accumulating A β -os and A β fibrils contact all cellular members of ANTs and NVUs. In Tg AD-model rodents, while acting as wardens, astrocytes sweep extracellular A β s by engulfing them via several A β -binding receptors, like LRP1 and LRP2/Megalin, and next proteolyse them. Eventually, ingested A β s are toxic for the astrocytes which before dying discharge them back into the extracellular milieu. This promotes the assembly of smaller senile plaques which are rich in glial fibrillary acidic protein (GFAP; Wyss-Coray et al., 2003; Nagele et al., 2004; Pihlaja et al., 2008). Thus, an

initially beneficial clearing of A β s surpluses by the astrocytes eventually competes with and wrecks their role as supporters of neurons metabolism (Pihlaja et al., 2008; Araque and Navarrete, 2010; Giaume et al., 2010; Halassa and Haydon, 2010; Mulder et al., 2012). In 3 \times Tg AD-model mice, as AD slowly yet inexorably progresses, the pattern of astrocytes' reactions changes. Astrocytes' processes rapidly wither and detach their shrouding end-feet from the tripartite synapses within the CA1 area and dentate gyrus. An early diffuse astrogliosis develops surrounding the senile plaques (Rodriguez-Vieitez et al., 2015).

Conversely, in human AD brains, astrocytes become hypertrophic, conserve their spatial domains, pierce with their processes A β senile plaques, lose part of their glutamate-metabolizing enzymes, over express GFAP, hyper polymerize actin, and make and release surplus amounts of cytokines and chemokines, such as S100 β , TNF- α , IL-1 β , IL-6, and IFN- γ -inducible protein-10 (IP-10). The secreted chemokines induce circulating leukocytes to cross the BBB and sustain a chronic neuroinflammation (Perez et al., 2010). In aMCI patients, but not in healthy individuals, an astrogliosis can be detected (using the [11] CD-deprenyl marker and Positron Emission Tomography) which abates during the progression toward full-blown AD (Choo et al., 2014). This human AD-related astrogliosis co-occurs with oxidative stress, extracellular accumulation of glutamate and/or K⁺, dyslipidemia, and/or folate deficit (Rojo et al., 2008; Li et al., 2011).

A belief has been prevailing for a long time, i.e., only a transneuronal diffusion of neurotoxic A β -os happens in AD. This view was experimentally modeled in retinoic acid-differentiated human SH-SY5Y neurons (Nath et al., 2012; Hallbeck et al., 2013). Conversely, astrocytes' own production and secretion of A β s as well as their potential contribution to AD progression was generally neglected. According to such a "classical" view, astrocytes only played the role of onlookers or at most of concierges cleansing neuronal debris and/or A β fibrils. Reports of astrocytes stuffed with A β ₄₂s in human brains with advanced LOAD strengthened this view (Nagele et al., 2004; Maragakis and Rothstein, 2006; Avila-Muñoz and Arias, 2014). Yet, because of their high numbers, even a token increase in astrocytes' A β s secretion rate would remarkably raise brain's load of A β s (Busciglio et al., 1993; Corbett and Buss, 2014). Nevertheless, recent studies have provided evidence that the intracerebral diffusion of A β ₄₂-os results from chemical interactions of astrocytes with neurons, oligodendrocytes, and microglia (Skaper et al., 2009; Bero et al., 2011; Dal Prà et al., 2015a). Such reciprocal exchanges *activate* the astrocytes which then express surpluses of APP and of β -S which act with γ -S to trigger an overproduction of A β s in several Tg AD-model mice (Rossner et al., 2005). The effects of exogenous A β s on mouse, rat, and human astrocytes and neurons have been studied *in vivo* and *in vitro*. Physiological patterns of astrocytes' intercellular Ca²⁺ waves and synchronous hyperactivity are changed in Tg AD-model animals (Kuchibhotla et al., 2009). When exposed to A β -os, newborn rat hippocampal astrocytes exhibited an increased intracellular Ca²⁺ concentration ([Ca²⁺]_i). Hence, a Ca²⁺ dyshomeostasis occurs in the astrocytes activated by AD (reviewed in Abramov et al., 2003; Mattson and Chan, 2003; Bezprozvanny and

Mattson, 2008; Berridge, 2014). Moreover, mouse astrocytes exposed to A β _{25–35} produced and secreted ceramide-stuffed exosomes ("apoxosomes") and prostate apoptosis response-4 (PAR-4) protein which would trigger the apoptotic demise of nearby neurons releasing A β s surpluses (Wang et al., 2012). In addition, primary cortical astrocytes from neonatal mouse pups treated with TNF- α + IFN- γ or A β ₄₂ (either in soluble or fibrillar form) raised the cells' levels of APP and β -S and their secretion rate of endogenous A β ₄₀ (yet, A β ₄₂ secretion was not assessed). The authors surmised that neuroinflammation triggers a feed-forward mechanism pushing the production of endogenous A β s in mouse astrocytes (Zhao et al., 2011).

As mentioned above, β -S and γ -S exhibit a discrete basal activity in untreated (control) NAHAs (Armato et al., 2013a). Once exposed to exogenous fibrillary or soluble A β _{25–35}—an A β ₄₂ proxy having the physical and biological features of A β ₄₂ (Kaminsky et al., 2010)—NAHAs start producing, accumulating, and secreting surplus A β ₄₂/A β ₄₂-os just as human cortical HCN-1A neurons do (Dal Prà et al., 2011; Armato et al., 2013a).

Under conditions of acute or chronic hypoxia, or during LOAD or when exposed to exogenous A β s, APP levels and both β -S and γ -S activities raise significantly thereby increasing A β s production and release (Perez et al., 2010; Dal Prà et al., 2011, 2014a,b; Takami and Funamoto, 2012). This might be due to A β ₄₂-os entering the nuclei and binding A β -interacting domains (A β IDs) in the APP and β -S genes promoters sequences causing their transcriptional activation (Bailey et al., 2011; Maloney and Lahiri, 2011; Barucker et al., 2014). Lastly, A β -activated microglia release cytokines, like IL-1 β or IFN- γ + TNF- α , that induce cultured adult human astrocytes to synthesize and secrete A β ₄₀ and A β ₄₂ (Blasko et al., 2000).

A β s AS RECEPTORIAL LIGANDS

As mentioned, an exposure to fibrillar or soluble A β _{25–35} elicits an excess production, accumulation, and secretion of A β ₄₂ and A β ₄₂-os in cultured NAHAs (Armato et al., 2013a; Dal Prà et al., 2015a). The primary molecular mechanism(s) underlying this exogenous A β s \Rightarrow endogenous A β s self-induction in NAHAs was (were) initially totally and still partly is (are) unclear. It appeared that exogenous A β s interacted with "something" located at the outer surface of the cells' plasma membrane (Kam et al., 2014; Jarosz-Griffiths et al., 2016). At the same time, the question arose whether this A β s self-inducing feed-forward mechanism worked in *human* neurons too, as it had been shown to do in A β -exposed rat cortical neurons and mouse hippocampal slices (Marsden et al., 2011). So would A β s bind and activate the signaling of one or more receptors? So far, several receptors have been indicated to interact with A β s (Table 1). Nevertheless, since A β s are the unique ligands for none of them, these A β •receptor interactions have been debated. Yet, once bound to A β s some of the receptors did undergo internalization and accumulated intracellularly (Kam et al., 2014; Jarosz-Griffiths et al., 2016). For example, highly specific soluble A β -os•CaSR complexes were shown to gather together and form patches at the plasma membrane of NAHAs prior to be internalized (Dal Prà et al., 2014a,b, 2015b).

TABLE 1 | Receptor interactions with various A β forms.

A β forms	Receptor	References
A β ₄₂ monomers	Insulin-like growth factor-1 receptor (IGF-1R)	Giuffrida et al., 2012
A β ₄₂ monomers	Low-density lipoprotein receptor-related protein 1 (LRP1)	Shibata, 2000; Kanekiyo et al., 2013, 2012
A β ₄₂ monomers	Low-density lipoprotein receptor (LDLR)	Castellano et al., 2012
A β ₄₂ monomers	Macrophage receptor with collagenous structure (MARCO)	Brandenburg et al., 2010
A β ₄₂ and A β ₄₀ monomers	Advanced glycation end products receptor (RAGE)	Du et al., 2012
A β ₄₂ and A β ₄₀ monomers	Apolipoprotein E (ApoE) receptor	Liu et al., 2013
A β ₄₂ monomers, A β ₄₂ -os	α 7 nicotinic acetylcholine receptor (α 7nAChR)	Wang et al., 2000; Jurgensen and Ferreira, 2010
A β ₄₀ monomers, A β ₄₂ -os	Cellular prion protein (PrP ^C)	Nygaard and Strittmatter, 2009; Pflanzner et al., 2012
A β ₄₂	Formyl peptide receptor (FPR1) Formyl peptide receptor-like 1 (FPRL1)	Iribarren et al., 2005; Doens and Fernandez, 2014
A β globulomers	P/Q-type Ca ²⁺ channels	Nimmrich et al., 2008
A β ₄₂ -os, A β ₄₀ -os	Frizzled (Fzd) receptor	Magdesian et al., 2008
A β ₄₂ -os	Insulin receptor	Zhao et al., 2008
A β ₄₂ -os	α -amino-3-hydroxy-5-methyl-4- isoxazole propionic acid receptor (AMPA)	Zhao et al., 2010
A β ₄₂ -os	Amylin 3 (AMY3) receptor	Fu et al., 2012
A β ₄₂ -os	NMDA-type glutamate receptor	Shankar et al., 2007
A β ₄₂ -os, A β fibrils	Calcium-sensing receptor (CaSR)	Ye et al., 1997; Conley et al., 2009; Dal Prà et al., 2014a,b, 2015b
A β ₄₂ -os, A β fibrils	p75 neurotrophin (p75 ^{NTR}) receptor	Perini et al., 2002; Chakravarthy et al., 2012
A β fibrils	SCARA1/2 (microglia) receptor	Wilkinson and El Khoury, 2012
A β fibrils	SCARB2/CD36 receptor	Stewart et al., 2010
A β fibrils	Toll-like receptor 2 (TLR2)	Doens and Fernandez, 2014
A β fibrils	Complement receptor type 3 (CR3)	Doens and Fernandez, 2014

Conversely, most of the fibrillar A β •CaSR complexes could not be internalized because of intrinsic mechanical hindrances and their persistent signaling likely altered crucial cellular functions with noxious and/or lethal consequences. This happened also in engineered SK-N-BE neuroblastoma cells over expressing the whole p75^{NTR} receptor which bound fibrillar A β s (Perini et al., 2002). Indeed, p75^{NTR} is also over expressed in the hippocampi of full-blown LOAD patients (Chakravarthy et al., 2012).

A clue on the topic was offered by observations that a mixture of three cytokines (i.e., TNF- α , IL-1 β , and IFN- γ) or soluble A β ₄₀ or fibrillar A β _{25–35} or A β _{1–42} induced a MEK/ERK1/2-mediated surplus NO production in NAHAs that could be fully suppressed when the cells were co-treated with a CaSR antagonist (or *calcilytic*) like NPS 89686 or NPS 2143 (Nemeth, 2002; Chiarini et al., 2005; Dal Prà et al., 2005; Armato et al., 2013a). Such results prompted us to investigate CaSR's interactions with A β s in human cortical astrocytes and neurons (Armato et al., 2012, 2013a).

THE CaSR IN THE SEVERAL NEURAL CELL TYPES

The readers looking for more details about the features of the CaSR are referred to other contributions in this special issue. Briefly, the CaSR is a member of family C of G-protein-coupled receptors (GPCRs). Its huge (~612 amino acids) extracellular N-terminal domain, named Venus Flytrap (VFT), is linked via a cysteine-rich region to seven transmembrane α -helices

(TM1–TM7) joined together by extracellular and intracellular loops altogether forming the 7TM region. Two domains of the CaSR's intracellular C-terminal tail are necessary for its expression at the cell surface and its composite signaling functions which are mediated by G-proteins (Armato et al., 2012). The two huge VFT lobes of functional CaSR homodimers bind orthosteric (type I) *agonists* like Ca²⁺ (the physiological ligand), various other divalent or trivalent cations, polyamines, and aminoglycoside antibiotics (Silve et al., 2005; Armato et al., 2012; Zhang et al., 2015). The allosteric (type II) CaSR ligands, like aromatic L- α -amino acids and highly selective *agonists* (or *calcimimetics*) and *antagonists* (or *calcilytics*) bind various 7TM sites (Nemeth, 2002; see also below). The CaSR swiftly senses any change in the [Ca²⁺]_e (Nemeth, 2002). Orthosteric type I agonists switch CaSR's signaling on owing to a rearrangement of its 7TM region permitting the receptor's C-tails to interact with various G proteins. The manifold CaSR's signaling pathways involve (i) second messenger-producing enzymes (e.g., adenylyl cyclase); (ii) phospholipases A2, C, and D; (iii) protein kinases (e.g., AKT, PKCs, MAPKs); (iv) Ca²⁺ influxes via TRPC6-encoded receptor-operated channels; and (v) transcription factors (TFs; reviewed in Zhang et al., 2015). Like other GPCRs, CaSRs display the “*ligand-biased signaling*” feature, i.e., a specific CaSR signaling pathway may be stably preferred over the others according to the ligand involved (Leach et al., 2015). Here we will briefly consider some pathophysiological effects of CaSR's signaling regarding the CNS.

The CaSR is expressed by all types of neural cells and by the endothelial cell and pericytes of the cerebral vessels

with a variable intensity, which for example is greater in the hippocampus (Chattopadhyay et al., 2000, 2008; Yano et al., 2004; Noh et al., 2015). In addition, cultured NAHAs also express functional CaSRs, less intensely when proliferating but more strongly when in mitotic quiescence. In any case, CaSR expression is unaffected by changes in the growth medium Ca^{2+} levels (Dal Prà et al., 2005).

CASR is a key player in genetic regulation of Ca^{2+} homeostatic system (Kapur et al., 2010). In addition, CaSR performs relevant roles outside the Ca^{2+} homeostatic system, as for example in the CNS (Riccardi and Kemp, 2012). Besides upholding local ionic homeostasis, brain cells' CaSRs modulate the proliferation, differentiation, and migration of neurons and oligodendrocytes during development; axonal and dendritic growth; axons myelination; neurons' and glial membrane excitability; olfactory and gustatory signal integration; presynaptic external Ca^{2+} signaling at *neocortex* nerve terminals; synaptic plasticity; and neurotransmission during perinatal and adult life. Importantly, an altered expression and/or dysfunction of the CaSR, as observed in CNS diseases like AD and ischemia/hypoxia/stroke, also deeply affects CaSR-dependent neurophysiological processes (Figure 2) (Chattopadhyay et al., 1999; Vizard et al., 2008; Bandyopadhyay et al., 2010; Chen et al., 2010; Armato et al., 2012, 2013a; Ruat and Traiffort, 2013; Kim et al., 2014; Dal Prà et al., 2014a,b, 2015a; Bai et al., 2015; Noh et al., 2015; Tharmalingam et al., 2016).

The first clue about a potential role for the CaSR in AD pathophysiology was the degeneration of hippocampal neurons ensuing $\text{A}\beta$ -induced peaks of cytosolic (intracellular) Ca^{2+} concentration ($[\text{Ca}^{2+}]_i$) (Brorson et al., 1995). A second clue was the assumed ability of fibrillar $\text{A}\beta_{25-35}$ or $\text{A}\beta_{1-40}$ to open Ca^{2+} -permeable non-selective cation channels (NSCCs) in hippocampal neurons of wild type (WT) $\text{CaSR}^{+/+}$ rats but not of $\text{CaSR}^{-/-}$ rats (Ye et al., 1997). The authors posited that $\text{A}\beta$ s could bind the CaSR since like polyamines they are endowed with orderly spaced arrays of positive charges. However, the same authors had previously observed hefty changes in pipette cations concentrations in cell-attached recordings and their replacement with Ca^{2+} had not affected channel amplitude or reversal potential (Ye et al., 1996a,b). Taken together, these results would have suggested the channel was alike permeable to K^+ and Na^+ or, alternatively, impermeable to cations like a Cl^- channel. However, the authors did not test his hypothesis. In this regard, several other authors have reported NSCCs being activated by *decreases* of calcium or other CaSR agonists (Hablitz et al., 1986; Xiong et al., 1997; Immke and McCleskey, 2001; Smith et al., 2004; Lu et al., 2010; Ma et al., 2012). Overall such findings do not corroborate the suggestion that $\text{A}\beta$ s activate NSCCs in neurons. Rather, $\text{A}\beta$ s would lessen the likelihood of NSCC openings or possibly activate Cl^- channels like probably the data from Ye et al. (1997) had demonstrated.

Afterwards, Conley et al. (2009) investigated the association of CASR gene variations in AD susceptibility using a cohort of 692 AD cases and 435 controls. A polymorphic dinucleotide repeat marker within intron 4 associated with AD, while three non-synonymous SNPs within exon 7 of the CASR gene associated with AD only in non-APOE $\epsilon 4$ carriers. In addition, TF activation

assays revealed that both apoE $\epsilon 4$ and $\epsilon 3$ (but not $\epsilon 2$) and exogenous $\text{A}\beta_{1-42}$ bound and activated CaSR's signaling. The authors concluded that the CASR plays a role in AD susceptibility in the absence of the APOE $\epsilon 4$ allele(s).

Subsequently, the formation of $\text{A}\beta$ s•CaSR complexes and their endocytosis was shown to occur in NAHAs by using the highly specific *in situ* proximity ligation assay (Dal Prà et al., 2014a,b, 2015b). As aforesaid, such $\text{A}\beta$ s•CaSR complexes elicited a surplus production and secretion of $\text{A}\beta_{42}$ and $\text{A}\beta_{42}$ -os from cortical NAHAs and HCN-1A neurons (Armato et al., 2013a). These observations imply that all types of human neural and cerebrovascular cells are susceptible to the neurotoxic effect(s) elicited by $\text{A}\beta$ •CaSR signaling.

CASR gene transcription is regulated by its promoters P1 and P2 which bind several TFs. Recently, the role of TFs in a number of genes associated with AD has been studied in detail. Interestingly, the CASR gene promoters bind several TFs which are involved also in the expression of AD-related genes. Thus, there exists a deeper than previously thought connection of CaSR expression regulation with AD pathophysiology (see Table 2 and references in it). Although CaSR mRNA and protein levels have not yet been investigated in human AD brains, it is likely that CASR's expression be altered in AD because of its co-regulation by some of the TFs implicated in the disease.

Besides the CaSR, $\text{A}\beta_{42}$ -os simultaneously link to many other surface receptors (Table 1) activating their signaling systems and changing ion balances prior to be endocytosed by all types of CNS cells. In so doing, $\text{A}\beta_{42}$ -os spark a dense clutter of cellular responses including mitochondrial over release of toxic ROS, Ca^{2+} surges via NMDARs' activation driving further mitochondrial releases of ROS, and production of toxic p-Tau oligomers (p-Tau-os) (Mao and Reddy, 2011; Müller et al., 2011; Swerdlow, 2011; Kam et al., 2014; Jarosz-Griffiths et al., 2016). The outcomes are the disconnection of neuronal networks—a cause of cognitive deterioration—and the damage and death of susceptible neurons eventually leading to full blown AD (Crimins et al., 2013; Kaye and Lasagna-Reeves, 2013; Medeiros et al., 2013).

However, the earliest asymptomatic stages of AD are still hard to detect because the build-up of highly toxic, synapse destroying $\text{A}\beta_{42}$ -os inside and outside neurons and astrocytes is imperceptible until senile plaques and NFTs remain undetectable (West et al., 2004; Selkoe, 2008a,b; Ferreira and Klein, 2011; Klein, 2013; Medeiros et al., 2013; Dal Prà et al., 2015a). Thus, in the course of several years the neurotoxic $\text{A}\beta_{42}$ -os spread stealthily from LEC's layer II to higher cognitive cortical areas (Khan et al., 2014) and the emergence of AD's typical hallmarks (Figure 1A). As it will be discussed below, these events are related to $\text{A}\beta_{42}$ -os•CaSR interactions whose signaling mechanisms are likely to underlie the developing amyloidosis in AD brains and hence have crucial therapeutic implications.

Some authors surmise a prion-like mechanism fostering the $\text{A}\beta_{42}$ -os (and p-Tau-os) diffusion in AD brains (Nussbaum et al., 2013; Morales et al., 2015). $\text{A}\beta_{42}$ -os extracted from AD brains could be passed on from retinoic acid-differentiated human SH-SY5Y donor neurons to similarly differentiated SH-SY5Y recipient neurons (Nath et al., 2012; Hallbeck et al., 2013). Most




FIGURE 2 | The main neural cell types origins, and the effects of Aβ₄₂-os accumulation without or with an added calcilytic. Top left: During development and in the adult, neurogenesis starts from NSCs that self-renew while giving birth to neurons and glial progenitors. From the latter (also named NG2 cells) stem both astrocytes and oligodendrocytes. All these cell types express the CaSR (see the text for details). **Top right:** When Aβ₄₂-os start accumulating in the brain tissues they soon block the NSCs self-renewal and differentiation of both neurons and oligodendrocytes from their respective precursors. The interactions of Aβ₄₂-os with the CaSRs (yellow ovals) elicits a surplus production/release of Aβ₄₂-os from neurons and astrocytes, of NO and VEGF-A from astrocytes, and of MBP and Aβ₄₂-os (not shown) from oligodendrocytes. All these toxic compounds together with later appearing p-Tau-os (not shown), microglial proinflammatory cytokines, and hypoxia/ischemia due to damaged micro vessels eventually cause an increasing death of neurons and oligodendrocytes (flanking skull and crossbones). **Bottom center:** The addition of calcilytic NPS 2143 (short termed here as NPS) thwarts all of the toxic effects elicited by Aβ₄₂-os•CaSR signaling like surplus secretion and diffusion of additional Aβ₄₂-os, NO, and VEGF-A, hindered differentiation of NSCs, and most of all, the death of neurons and oligodendrocytes, vascular damage, the later p-Tau-os appearance, and likely microglial activation (the latter two not shown). The findings on neurons and astrocytes indicate the feasibility of calcilytics as anti-LOAD therapeutics capable of halting Aβ₄₂-os self-promoting and self-maintaining mechanisms (Dal Prà et al., 2015a).

TABLE 2 | Comparison between CaSR and AD-related genes transcriptional regulators.

Gene	Transcription factor	References
CaSR	SP1/3* , AP1 , STAT1/3 , NFκB , TFIID , Vitamin D, GCM-2	Santpere et al., 2006; Hendy et al., 2013
APP	SP1 , AP1 , STAT1/3 , NFκB , USF, CTCF, HSF1, SP1-like, UBP, HIF-1α , CREB , GATA1	Theuns and Van Broeckhoven, 2000; Santpere et al., 2006; Chen et al., 2013
BACE1	SP1 , STAT1/3 , NFκB , HIF-1α, PPAR γ	Santpere et al., 2006; Wen et al., 2008; Chen et al., 2013
PSEN1	SP1 , Ets, CREB	Theuns and Van Broeckhoven, 2000; Santpere et al., 2006; Chen et al., 2013
APOE	SP1 , TFIID , AP-2 , URE3BP, PPARγ	Theuns and Van Broeckhoven, 2000; Santpere et al., 2006; Chen et al., 2013;
MAPT	SP1 , AP-2 , Nrf1, MTF1, MBF1, Mepl, GCF	Santpere et al., 2006; Cailliet-Boudin et al., 2015

*Shared transcription factors are in bold characters.

important, an Aβ₄₂-os propagation within the brains of Tg APP-model mice or WT rats or marmoset (*Callithrix jacchus*) monkeys also obtained via injections of AD brain extracts or punctures made with steel wires coated with the same extracts (Maclean et al., 2000; Meyer-Luehmann et al., 2006; Eisele et al., 2009; Langer et al., 2011; Hamaguchi et al., 2012; Rosen et al., 2012). In such animal models, the diffusion of the injected Aβ₄₂-os followed the same route as developing AD pursues in humans, i.e., LEC layer II ⇒ perforant pathway ⇒ hippocampal dentate gyrus and CA3 area ⇒ upper cortical regions (Morrison and Hof, 2007; Khan et al., 2014). Besides, a cerebrovascular amyloidosis was induced after a delay of various months by intraperitoneal injections of 1000-fold higher doses of Aβ₄₂-os-charged mouse brain extracts (Eisele et al., 2010). The mechanisms by which misfolded Aβ₄₂-os (and p-Tau-os) propagate within the brain are undetermined (Moreno-Gonzalez and Soto, 2011). So far, the prion-like intrabrain spreading potential of Aβ₄₂-os appears to be feeble as compared to the infectious capabilities proper of true prions and to require a direct contact with the neural cells (Aguzzi and Rajendran, 2009; Irwin et al., 2013). In addition, an Aβ₄₂-os amplifying mechanism has simultaneously to operate in order to assist the prion-like diffusion of the brain amyloidosis (Brettschneider et al., 2015). Hypothetically, this amplifying mechanism might result from or be aided by the Aβ₄₂-os own self-induction and self-spreading properties due to their interaction with the CaSRs of neurons, astrocytes, and other brain cell types (Dal Prà et al., 2015a).

Aβ•CaSR SIGNALING PROMOTES INTRA- AND EXTRACELLULAR TOXIC Aβ₄₂/Aβ₄₂-OS OVERLOADS

By using as preclinical models *in vitro* cortical nontumorigenic NAHAs and postnatal HCN-1A neurons brought to a complete proliferative quiescence, exogenous Aβ_{25–35}-os and Aβ_{1–42}-os

were shown to bind the plasma membrane-inserted CaSRs with a high specificity. These bonds activated CaSR's intracellular signaling pathways which in turn elicited a whole set of pathophysiological effects in both cell types, including the death of the HCN-1A neurons (summarized in **Table 3**; (Dal Prà et al., 2011, 2014a,b, 2015a,b; Armato et al., 2013a; Ruat and Traiffort, 2013). As mentioned, an Aβ-os•CaSR-activated MEK/ERK-dependent pathway mediated NO overproduction in NAHAs; the same signaling stabilized the HIF-1α•HIF-1β TF which then entered the astrocytes' nuclei to trigger a VEGF-A surplus production and secretion (Dal Prà et al., 2005, 2014b).

By contrast, the mechanisms of the increased synthesis, accumulation, and release of Aβ₄₂-os elicited through Aβ-os•CaSR signaling in both NAHAs and HCN-1A neurons are not as yet fully understood and currently under investigation. In regard to this topic, an upregulation of the CaSR and an intensified Aβ-os•CaSR signaling induced the death of neurons in rodent models of cerebral ischemia/hypoxia/stroke (Kim et al., 2014). This is a second instance besides LOAD in which Aβ-os•CaSR signaling kills neurons.

NEUROTOXIC Aβ•CaSR INTERACTIONS IN OTHER GLIAL AND CEREBROVASCULAR CELLS

The extremely complex mammalian CNS harbors several distinct cell types. Generally, LOAD discussions focus most on neurons, less on microglia, but leave the other cell types in the shade. However, several authors have tried to broaden this restricted viewing by putting astrocytes into the fray (Busciglio et al., 1993; Blasko et al., 2000; Chiarini et al., 2005; Li et al., 2011; Zhao et al., 2011; Armato et al., 2013a; Dal Prà et al., 2015a). Indeed, in our work we have been using both NAHAs and HCN-1A neurons as separate models to clarify the responses evoked by an exposure to exogenous Aβ-os. Hence, we do not deem astrocytes being more important players than neurons in LOAD promotion. Instead, we have been endorsing a holistic view, i.e., all CNS cell types are likewise important players both in CNS physiology and LOAD pathophysiology. Consequently, we review below relevant knowledge concerning the CaSR with respect to LOAD in the remaining glial cell types and cerebrovascular cells.

Oligodendrocytes

Oligodendrocytes precursors (NG-2 glial cells) generate also protoplasmic astrocytes (**Figure 2**) and maybe neurons, and receive synaptic inputs. These precursors become functionally impaired and/or damaged with aging (reviewed in Cai and Xiao, 2016). When NSCs' differentiation is aimed at the oligodendrocyte lineage, the expression and activity of NSCs' CaSRs are up-regulated, which favors their expansion and differentiation (Chattopadhyay et al., 2008). Human oligodendrocytes keep amplifying their numbers up to 5 years of age, when they amount to ~5–10% of the total glia. Thereafter, their turnover remains negligible. Typically, oligodendrocytes' myelin production and myelin sheaths' upkeep quickly adapt to ongoing needs, e.g., learning activities—a feature promoting

TABLE 3 | Harmful effects A β -CaSR signaling elicits in human neurons and astrocytes.

Cell type	Stimulus	Pathological effect	Effect of adding calcilytic to A β s	Effect of calcimimetic alone
Neurons, astrocytes	A β_{42} -os A β fibrils	Overproduction and diffuse intracellular accumulation of endogenous A β_{42} monomers and A β_{42} -os due to an increased β -S and γ -S activity and (likely) to decreases in A β proteolysis	Total suppression of intracellular accumulation of A β_{42} monomers and A β_{42} -os due to increased A β -os proteolysis (no effect on increased β -S and γ -S activities)	No apparent intracellular accumulation of A β s
Neurons, astrocytes	A β_{42} -os A β fibrils	Concurrent A β_{40} -os intracellular accumulation	Modest decrease of A β_{40} -os intracellular accumulation	n. d.*
Neurons, astrocytes	A β_{42} -os A β fibrils	Surplus secretion of A β_{42} -os, but not of A β_{40} -os, along the Golgi/trans-Golgi pathway and axons \Rightarrow extracellular A β_{42} /A β_{40} ratios values shift to the cytotoxic range	Total suppression of surplus release of A β_{42} -os along the Golgi/trans-Golgi pathway and axons, but increased release of A β_{40} -os \Rightarrow extracellular A β_{42} /A β_{40} ratios values remain in the normal range (NPS 2143 by itself exerts no effect on basal A β_{42} -os secretion)	Significant surplus secretion of A β_{42} -os
Neurons	A β_{42} -os A β fibrils	Slow yet progressive death by apoptosis of the human cortical neurons (<i>in vivo</i> this is the cause of cognitive decline; Nelson et al., 2012).	Neurons remain alive and kicking	n. d.
Astrocytes	A β_{42} -os A β fibrils	NAHAs survive and keep making and releasing neuron-harming compounds (see below)	No apparent effect on survival	n. d.
Astrocytes	A β fibrils	Increased activity of the glycogen synthase kinase (GSK)-3 β , one of the main Tau kinases (Armato et al., 2013b).	Total suppression of the surge of GSK-3 β activity (Armato et al., 2013b).	n. d.
Astrocytes	A β_{42} -os A β fibrils	Stabilization and nuclear translocation of the HIF-1 α •HIF-1 β transcription factor \Rightarrow expression of VEGF-A, APP, and BACE1 genes \Rightarrow heightened synthesis/secretion of VEGF-A and A β_{42} /A β_{42} -os	HIF-1 α destabilization \Rightarrow deep yet transient decrease of nuclear HIF-1 α •HIF-1 β transfer \Rightarrow no surplus production/release of VEGF-A, APP, and A β_{42} /A β_{42} -os	n. d.
Astrocytes	A β_{42} -os, A β fibrils	Significant yet transient surge of total CASR protein	Downregulation of total CaSR protein: modest and transient with NPS 2143 alone but fast, intense and persistent with A β s + NPS 2143	No change in total CaSR protein
Astrocytes	A β_{42} -os A β fibrils	Induction and MEK/ERK-dependent activation of GTP cyclohydrolase-1 (GCH1) \Rightarrow production of BH4 (tetrahydrobiopterin) \Rightarrow dimerization and activation of the concomitantly induced NO synthase (NOS)-2 \Rightarrow excess release of NO	Inactivation of GCH1 \Rightarrow lack of BH4 \Rightarrow no dimerization and activation of the concomitantly induced NO synthase (NOS)-2 \Rightarrow no overproduction of NO	n. d.

*n.d., not determined.

neural plasticity. During AD development, at neurotoxic levels (i.e., in the μ M range) A β -os switch off the Wnt signaling of the precursors thereby hindering their differentiation into oligodendrocytes (Figure 2; Barateiro et al., 2016). In advanced AD, soluble and fibrillar A β s and/or p-Taues/NFTs together with ongoing oxidative stress and neuroinflammation cause oligodendrocytes' to dysfunction and die via apoptosis (reviewed in Cai and Xiao, 2016). Consequently, myelin sheaths break down first in the hippocampus and fornix, and later in the other involved areas (Roth et al., 2005). The breakdown of myelin sheaths releases myelin basic protein (MBP), which by itself triggers a neurotoxic discharge of NO from cortical NAHAs. This MBP effect is synergistically amplified by a mixture of three proinflammatory cytokines (TNF- α , IL-1 β , and IFN- γ) or by soluble A β_{40} (Chiarini et al., 2005). So far, the specific neurotoxic effects of A β -os•CaSR signaling have not been

investigated in human oligodendrocytes, although doing it would be worthwhile. Interestingly, mature oligodendrocytes are able to express APP and to produce and secrete both A β_{42} and A β_{40} (Skaper et al., 2009). Therefore, besides neurons and astrocytes, oligodendrocytes are the third potentially relevant source of endogenous A β_{42} -os in LOAD—a source hitherto disregarded perhaps because of its progressive cytotoxic damage and destruction. Thus, a crucial role of A β -os•CaSR signaling in the neurotoxic responses and demise of oligodendrocytes in AD remains to be proven.

Microglia

At variance with neural cells, microglia arise from circulating myeloid monocytes which migrated into the CNS during gestation to act there as macrophage equivalents. In their physiologically “quiescent” phenotype, microglia promote

brain development and relevantly upkeep neural environment homeostasis, immunological surveillance, modulation of neuronal proliferation and differentiation, pruning of synapses, and clipping of apoptosing neurons (Saijo and Glass, 2011; Harry, 2013). Microglia become “activated” in response to neural tissue injury and then start sweeping up debris from degenerated neurons and infectious agents (when present), hence favoring tissue repair (Yang et al., 2010; Lee et al., 2011; Derecki et al., 2013; McGeer and McGeer, 2015). Moreover, in AD microglia are persistently activated, keep engulfing extracellularly accumulating fibrillar and soluble A β s, and surround and infiltrate dense core senile plaques where they promote A β s fibrillation (reviewed in Rosen et al., 2012). Additionally, both A β fibrils and A β ₄₂-os trigger the microglia to secrete proinflammatory cytokines, (e.g., IL-1 β , TNF- α , IFN- γ), chemokines (Lindberg et al., 2005; Färber and Kettenmann, 2006; Kawanokuchi et al., 2006; Saijo and Glass, 2011; Heneka et al., 2013; Prokop et al., 2013), ROS, NO, and even N-terminally truncated A β -os (Nagele et al., 2004; Mawuenyega et al., 2010; Oberstein et al., 2015). The interaction of ROS and NO generates hyper toxic peroxynitrites (ONOO⁻). Therefore, both microglia and astrocytes contribute to kindle and keep going the chronic neuroinflammation proper of LOAD brains. Furthermore, the microglial cytokines bind and activate their specific receptors on the surface of the astrocytes which are thus stimulated to produce and release additional amounts of A β -os, NO, and VEGF-A besides the amounts of the same agents generated by the astrocytes own A β -os•CaSR signaling (Dal Prà et al., 2005, 2015a; Chiarini et al., 2010). In turn, these microglia-elicited astrocytes' secretions sustain and/or intensify microglia activation, starting vicious cycles of astrocytes \leftrightarrow microglia reciprocal interactions. They also stimulate the adjoining ANTs to produce additional A β ₄₂-os that keep spreading and via A β -os•CaSR signaling elicit the release of (a) further amounts of A β ₄₂-os from neurons and astrocytes; (b) NO and VEGF-A from astrocytes; (c) MBP and A β ₄₂-os from oligodendrocytes; and (d) proinflammatory cytokines, chemokines, ROS, NO, and N-terminally truncated A β s from microglia (Blasko et al., 2000; Lindberg et al., 2005; Kawanokuchi et al., 2006; Mandrekar-Colucci and Landreth, 2010; Zhao et al., 2011; Prokop et al., 2013; Oberstein et al., 2015). Thus, self-maintaining and spreading vicious cycles of reciprocal interactions between microglia and ANTs' members keep exerting significant toxic effects on all neural cell types (Nath et al., 2012) strongly promoting as a result LOAD progression (Rojo et al., 2008; Nordberg, 2014). However, likely for cytotoxic reasons microglia's inflammogenic role decreases with the progressing of AD (Mizuno, 2012), and it may even become less relevant than astrocytes' role due to the greater numbers, stronger resistance to toxic agents, and longer-lasting functional activation of the astrocytes (reviewed in Rosen et al., 2012).

Moreover, the specific outcomes of the interactions between exogenous A β ₄₂-os and microglial CaSRs of WT and AD-model rodents are still undefined notwithstanding their potential relevance to LOAD therapy (McGeer and McGeer, 2015). Notably, rat microglia express a functional CaSR capable of modulating a Ca²⁺-activated K⁺ channel (Chattopadhyay et al.,

1999; Yano et al., 2004). In this regard, we recall that the BV-2 immortalized murine microglial cell line was reported to constitutively produce and release A β s. Moreover, and remarkably, adding exogenous A β _{25–35} or lipopolysaccharide increased the production and secretion of A β s from BV-2 microglial cells (Bitting et al., 1996). The authors did not assess the CaSR's role in this process. Nevertheless, the findings of Bitting et al. (1996) and Oberstein et al. (2015) indicate microglia as a likely fourth *source* of A β -os in LOAD brains. As far as we know, no study about the CaSR in *human* microglia has been reported. Therefore, the role of A β -os•CaSR signaling in microglia deserves further investigations.

Cerebral Vessels

Astrocytic processes' end-feet envelop the cerebral micro vessels forming functional NVUs which govern the delivery of nutrients and oxygen required for the activities of ANTs' neurons (**Figure 1B**). In LOAD, accumulating A β ₄₂-os, A β fibrils, and NO harm the cells of the cerebral vessels eventually causing the onset of a cerebral amyloid angiopathy (CAA) which helps advance LOAD (Nelson et al., 2016). CAA's degenerative changes include perivascular ring-like A β s casts staving off astrocytic processes' end-feet, increased vessel walls stiffness, weakened responses to astrocyte-released vasodilator agents, impeded neoangiogenesis, and changed BBB permeability, altogether causing local hypoxic/ischemic lesions (Kimbrough et al., 2015; Love and Miners, 2015). The latter favor the production/release of A β ₄₂-os surpluses, likely via A β ₄₂-os•CaSR signaling from adjoining ANTs' components thus hastening cognitive decline (reviewed in Helman and Murphy, 2016). The endothelial cells of human aorta and other vessels express the CaSR (Ziegelstein et al., 2006). By inference, the endothelia and other cellular components of the human brain vessels' walls should also express the CaSR. Then again, to our knowledge, no study has specifically addressed the potential toxic effects of A β -os•CaSR signaling on the cerebrovascular walls pericytes, smooth muscle cells, and endothelial cells in LOAD. Finally, yet importantly, LOAD-damaged blood vessels can block neurogenesis from NSCs in the subventricular zone and hippocampus (**Figure 2**) thereby thwarting the processing and storage of new memories (Licht and Keshet, 2015).

In summary, the interactive dysfunctional responses of all brain-resident cell types evoked via A β -os•CaSR signaling are likely to play significant roles in the promotion of LOAD (Brorson et al., 1995; Dal Prà et al., 2015a).

A β -os•CaSR INTERACTIONS ADVANCE LOAD PROGRESSION

During AD development, ANTs' vital functions can turn into grievously troublesome ones. When the “client” neurons and their “master” astrocytes of small *foci* in the LEC's layer II overproduce A β ₄₂ monomers, they start releasing A β ₄₂-os into the synaptic spaces surrounded by the astrocytes' shrouding end-feet and into the extracellular milieu. When A β ₄₂-os spread to the CA1 area, the formation of new memories begins to fail

(Bushong et al., 2002). We already mentioned that ANTs' neurons and astrocytes are endowed with a variety of $A\beta_{42}$ -os-binding receptors, including the CaSR (Table 1). Next, released $A\beta_{42}$ -os scatter from the ANTs of origin to contiguous ANTs, in which they bind and activate the local neurons' and astrocytes' CaSRs (Dal Prà et al., 2015a). As a result, both cell types start producing and releasing additional $A\beta_{42}$ -os, which will keep spreading and targeting the CaSRs of neurons and astrocytes of remoter ANTs (Figure 3). Remarkably, $A\beta_{42}$ -os diffuse not only by contiguity, but also by apparent "jumps" because the blighted hippocampal neurons project their long axons carrying $A\beta_{42}$ -os surpluses to the *neocortex* of far-off cerebral lobes (Figure 1A). Thus, reiterating feed-forward cycles of this kind which sustain and amplify themselves via $A\beta_{42}$ -os•CaSRs interactions end up recruiting the neurons and astrocytes of ever-increasing numbers of ANTs. The latter will make and release still more $A\beta_{42}$ -os which will spread to even farther off ANTs. Thus, from the LEC LOAD neuropathology would reach through this basic molecular mechanism upper cerebral cortical areas (Dal Prà et al., 2015a). $A\beta_{42}$ -os•CaSRs and $A\beta_{42}$ -os•PRP^Cs interactions would next favor the gradual appearance of p-Tau-os which at some later point will acquire via still undefined mechanism(s) the ability to self-induce themselves and spread independently of $A\beta_{42}$ -os. Afterwards, both toxic drivers would hasten AD progression toward its gloomy conclusion (Dal Prà et al., 2015a).

PHARMACOLOGICAL CaSR MODULATORS AND LOAD

Various synthetic phenyl alkylamines derivatives endowed with two-to-four aromatic rings and NH^{3+} groups selectively act either as CaSR's type II allosteric agonists (or *calcimimetics*; e.g., NPS R-568, Cinacalcet, and AMG 416) or antagonists (or *calcilytics*; e.g., NPS 89636, NPS 2143). Such agents shift to the right or to the left, respectively, the CaSR's response curve to changes in extracellular Ca^{2+} concentration ($[Ca^{2+}]_e$) (Nemeth, 2002; Saidak et al., 2009; Widler, 2011). These CaSR modulators bind distinct sites in the 7TM region—both calcimimetics and calcilytics between TM6 and TM7, but calcilytics alone between TM3 and TM5 (Petrel et al., 2004). The full therapeutic potential of CaSR modulators has yet to be gauged in human ailments (Saidak et al., 2009; Widler, 2011; Ward et al., 2012; Nemeth, 2015). These agents too can promote the "ligand-biased signaling" according to the specific cell type considered—a feature that might favor target-specific therapeutic approaches (Davey et al., 2012; Leach et al., 2015).

Calcimimetics

NPS R-568 and Cinacalcet are presently the best paradigms of allosteric CaSR agonists as they hinder PTH secretion (Nemeth, 2004, 2013). In clinical settings, Cinacalcet has been and still is used to manage primary hyperparathyroidism and secondary hyperparathyroidism due to chronic kidney disease (CKD). It has been used particularly in patients in chronic dialysis, although in some of these cases it failed to be effective (Nemeth and Goodman, 2015; Brunaud et al., 2016). Cinacalcet also averts or

reverses parathyroid hyperplasia in rats and functionally rescues CaSR's loss-of function mutations (Nemeth, 2004, 2013; Miller et al., 2012; Nemeth and Shoback, 2013; Palmer et al., 2013; Nemeth and Goodman, 2015; Mayr et al., 2016). However, since CaSR expression is ubiquitous, one should not overlook that calcimimetics (and calcilytics) may exert PTH-independent effects in tissues, brain included, other than the parathyroid glands (Massy et al., 2014). As an example, a Cinacalcet-triggered protracted CaSR signaling curtailed the mitotic activity and interfered with the remodeling and barrier function of oesophageal epithelial cells via catenin-cadherin complexes disruption, actin cytoskeletal changes, and CaSR reallocation to the nuclei (Abdulnour-Nakhoul et al., 2015). Various pieces of evidence discussed in previous sections have denoted the CaSR's involvement in AD onset and progression. Remarkably, calcimimetic NPS R-568 mimics at least one pathological effect of $A\beta$ s•CaSR signaling: it significantly increases the amount of $A\beta_{42}$ -os secreted by cortical NAHAs (Armato et al., 2013a; Dal Prà et al., 2015a; Table 2). The potential clinical implications of this NPS R-568 effect deserve further assessment.

Calcilytics

Compounds like NPS 2143, NPS 89636, Calhex, etc., desensitize the CaSR to $[Ca^{2+}]_e$ changes and characteristically increase PTH secretion (Nemeth, 2004, 2013). Various calcilytics were initially tested as therapeutics for postmenopausal osteoporosis. But, they lacked effectiveness because they elicited a PTH oversecretion which stimulated in parallel both osteogenesis and osteolysis. This stopped any further clinical testing concerning a potential anti-osteoporosis activity of calcilytics (Nemeth, 2004, 2013; Nemeth and Shoback, 2013; Nemeth and Goodman, 2015). Novel indications for calcilytics are (i) idiopathic hypercalciuria; and (ii) autosomal dominant hypocalcaemia due to CaSR's gain-of-function mutations; as for the latter condition calcilytic NPS P-795 is being tested as a therapeutic in clinical trials (White et al., 2009; Letz et al., 2010; Park et al., 2013; Nemeth, 2015; Nemeth and Goodman, 2015). In addition, calcilytics may mitigate the airways hyper responsiveness and inflammation proper of asthma (Yarova et al., 2015). Calcilytics also inhibit the cellular hyper proliferation typical of pulmonary artery idiopathic hypertension (Yamamura et al., 2012, 2015).

A further potential indication of calcilytics is LOAD (Armato et al., 2013a). In fact, we showed that in cultured *human* untransformed cortical NAHAs and HCN-1A neurons calcilytics NPS 2143 and NPS 89696 counteracted *all* the noxious consequences—death of the neurons included—brought about by $A\beta$ s•CaSR signaling (Table 3; Armato et al., 2013a; Dal Prà et al., 2014a,b, 2015a). These preclinical findings indicate that, by hindering the $A\beta$ s•CaSR signaling at the level of neurons, of all glial cell types, and of cerebrovascular cells, calcilytics would effectively suppress (or at least significantly mitigate) the intracerebral propagation of the amyloidosis and its concurrent neurotoxic effects. By keeping the neurons alive and functioning, calcilytics would safeguard the patients' cognitive faculties. Most remarkably, calcilytics would be the so far unique anti-LOAD therapeutics simultaneously targeting a number of

FIGURE 3 | Continued

Blue arrows indicate the diffusion of $A\beta_{42}$ -os from neurons to astrocytes (red solid circles) and from astrocytes to neurons (green solid circles). Numbers 1–5 also suggest possible sequences of events both intra- and inter-ANTs. While the involved cells undergo cytotoxic changes, including the early death of some neurons (*in green color with skull and crossbones aside*), the newly released $A\beta_{42}$ -os spread and reach both neighboring and remoter ANTs (*short and long red arrows*), starting via $A\beta_{42}$ -os•CaSR signaling new cycles of surplus production and secretion of endogenous $A\beta_{42}$ -os. The latter will disperse and engage nearby and still farther away ANTs (not shown) again triggering the same kind of $A\beta_{42}$ -os•CaSR signaling-triggered pathological responses, including additional $A\beta_{42}$ -os oversecretion and neuronal deaths. Thus, $A\beta_{42}$ -os spread can affect local ANTs (as embodied here by the *short and long red arrows*) or remoter ANT via projecting axons carrying the $A\beta_{42}$ -os (as exemplified here by the *big black arrows*).

LOAD-promoting processes which $A\beta$ s•CaSR signaling triggers in all types of CNS cells (Armato et al., 2012, 2013a; Dal Prà et al., 2014a,b, 2015a). Calcilytics reduce neuronal death also in animal models of ischemia/hypoxia/stroke, i.e., in conditions that increase $A\beta$ -os production in the affected brain area(s) (Kim et al., 2014; Bai et al., 2015). These findings too strongly substantiate our hypothesis about the crucial role of the CaSR in AD.

Here, some pharmacological notations are in order. Being lipid-soluble, calcilytics cross the BBB, can be administered by any route (oral, etc.), and in the presence of exogenous soluble $A\beta$ -os or fibrillar $A\beta$ s (which also release $A\beta$ -os) selectively antagonize CaSRs signaling and intensely down regulate the CaSRs of human cortical astrocytes, and likely neurons and other CNS cells (Armato et al., 2013a; Dal Prà et al., 2015a). Calcilytic NPS 2143 is well tolerated by rodents (Nemeth, 2002; Kim et al., 2014). Recent NPS 2143 derivatives, which stimulate PTH secretion less intensely, were well withstood by human subjects during phase I and phase II clinical trials aimed at assessing the drugs' anti-osteoporosis activity (in such instances no consideration was given to brain-related effects; Nemeth and Shoback, 2013; John et al., 2014). Of late, the NMDA receptor inhibitors Memantine and Nitromemantine and the Fyn kinase inhibitor Saracatinib (AZD0530) were suggested as therapeutics to offset the neurotoxic actions brought about by extracellularly gathering $A\beta$ -os (Talantova et al., 2013; Kaufman et al., 2015). It should be realized that the calcilytics' target, i.e., the CaSR, holds an *upstream* place with respect to NMDARs and Fyn. Therefore, calcilytics' ability to hinder any extracellular $A\beta_{42}$ -os build-up would as well prevent any downstream $A\beta_{42}$ -os harmful effects involving NMDARs and Fyn. Moreover, by keeping the extracellular $A\beta_{42}/A\beta_{40}$ ratio values within the physiological range, calcilytics would thwart any cytotoxic effects and hindrance of NSCs differentiation (**Figure 2**) and of functions necessary for neurogenesis to occur in the dentate gyrus subgranular zone. Calcilytics would also safeguard the structural and functional integrity of cognition-critical upper cerebral cortical areas (Choi et al., 2013; Lee et al., 2013; Barateiro et al., 2016). In short, calcilytics would preserve the patients' ability to store and retrieve memories and to cope with daily needs, thus improving her/his life's quality and prospects.

Calcilytics' failure as therapeutics for osteoporosis due to the double-edged effects of PTH was a stroke of ill-luck (Nemeth, 2004, 2013; Nemeth and Shoback, 2013; Nemeth and Goodman, 2015). In addition, calcilytics' potential side effects—e.g., mild hyperparathyroidism in humans, hypertension in rats—shied people away from considering their use in clinical settings.

However, calcilytics' rather mild side effects must be carefully weighed against the harsh fact that *symptomatic LOAD inexorably kills the patient cognitively several years before her/his actual physical demise*. Hence, just as anticancer chemotherapeutics are used notwithstanding their potential side effects, once clinical trials have proven calcilytics therapeutic effectiveness, their side effects will be a trivial toll against preventing/stopping LOAD progression.

CONCLUSIONS AND FUTURE PERSPECTIVES

Astrocytes' and neurons' pathophysiology in LOAD brains are quite intricate and specific for each animal species, brain area, aging phase, and stage of the illness. Therefore, a deeper understanding of AD-related metabolic events occurring in human cortical untransformed astrocytes and neurons has helped and will help identify ground breaking therapeutic approaches to LOAD. Differently from neurons, human astrocytes survive for lengthy terms the exposure to toxic amounts (in the μ M range) of soluble or fibrillar $A\beta$ s while undergoing complex and only partially understood functional changes collectively defined as *activation*. The latter include, amongst others, alterations of (a) the $A\beta$ • α 7-nAChR signaling affecting the intra- and intercellular Ca^{2+} signaling and gliotransmitters secretion, and (b) the $A\beta$ •CaSR signaling triggering a surplus production and secretion of neurotoxic $A\beta_{42}$ -os, VEGF-A, and NO. However, since the CaSR is endowed with panoply of intracellular signaling pathways, we undertake that not all of the toxic metabolic effects prompted by $A\beta$ •CaSR signaling have been yet identified in human neural cells. Moreover, the interactions of $A\beta$ s with receptors other than the CaSR and/or $A\beta$ s-mediated non-receptorial mechanisms add other neurotoxic factors (e.g., proinflammatory cytokines, chemokines, ROS, etc.) which confound the picture. Collectively, these manifold metabolic responses reveal the deep involvement of astrocytes in LOAD's promotion. This view is strengthened by a recent report demonstrating that, while human neurons release only $A\beta_{1-42}$, human astrocytes secrete a remarkable amount of N-terminally truncated $A\beta$ s, including $A\beta_{3-42}$ moieties that are transformed into the utterly toxic pE- $A\beta_{3-42}$ (Gunn et al., 2010; Morawski et al., 2014; Oberstein et al., 2015). However, here one should not overlook that oligodendrocytes and microglia and the cellular components of cerebral vessels also express the CaSR. Therefore, toxic $A\beta$ •CaSR interactions do also occur at the level of the latter cell types which may induce the

production and release of further amounts of A β ₄₂-os thereby helping advance AD progression. This field is worth exploring further because white matter damage, neuroinflammation, and local hypoxia/ischemia/stroke play relevant roles in LOAD pathophysiology.

It is noteworthy that allosteric CaSR antagonists or calcilytics can suppress upstream all the downstream toxic consequences of A β •CaSR signaling in both human neurons and astrocytes, and likely might do the same in all other neural and vascular cell types of the CNS. These findings make us posit that calcilytics would effectively prevent LOAD amyloidosis from spreading. Moreover, by hindering A β ₄₂-os accumulation and diffusion calcilytics would prevent also the ensuing appearance and spread of the p-Tau-os and their lethal cooperation with A β ₄₂-os (Dal Prà et al., 2005, 2014a,b, 2015a; Armato et al., 2013a).

In conclusion, these findings attest the need to increase our understanding of CaSRs pathophysiology in all types of human untransformed neural cells. In fact, one cannot disregard that meanwhile LOAD is flaring up worldwide in an epidemic-like fashion. Therefore, it would be timely to validate the anti-LOAD

effectiveness of calcilytics in clinical trials recruiting aMCI and/or early symptomatic patients.

AUTHOR CONTRIBUTIONS

AC, ID, and UA contributed equally to the manuscript's conception. DL made searches and helped with the manuscript.

FUNDING

This work was supported by the Italian MIUR (Ministero dell'Istruzione, dell'Università e della Ricerca) via FUR 2013, FUR 2014, FUR 2015, and FUR 2016 funds allotted to AC, ID, and UA.

ACKNOWLEDGMENTS

ID, AC, and UA were supported by FUR 2013, FUR 2014, FUR 2015, and FUR 2016 funds from the MIUR. DL holds a PhD fellowship in Experimental Medicine from the MIUR.

REFERENCES

- Abdulnour-Nakhoul, S., Brown, K. L., Rabon, E. C., Al-Tawil, Y., Islam, M. T., Schmiege, J. J., et al. (2015). Cytoskeletal changes induced by allosteric modulators of calcium-sensing receptor in esophageal epithelial cells. *Physiol. Rep.* 3:e12616. doi: 10.14814/phy2.12616
- Abramov, A. Y., Canevari, L., and Duchen, M. R. (2003). Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. *J. Neurosci.* 23, 5088–5095.
- Abramov, E., Dolev, I., Fogel, H., Ciccotosto, G. D., Ruff, E., and Slutsky, I. (2009). Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. *Nat. Neurosci.* 12, 1567–1576. doi: 10.1038/nn.2433
- Aguzzi, A., and Rajendran, L. (2009). The transcellular spread of cytosolic amyloids, prions, and prionoids. *Neuron* 64, 783–790. doi: 10.1016/j.neuron.2009.12.016
- Alzheimer's Association (2012). Alzheimer's disease facts and figures. *Alzheimers Dement.* 8, 131–168. doi: 10.1016/j.jalz.2012.02.001
- Antanitus, D. S. (1998). A theory of cortical neuron-astrocyte interaction. *Neuroscientist* 4, 154–159. doi: 10.1177/107385849800400310
- Araque, A., and Navarrete, M. (2010). Glial cells in neuronal network function. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 385, 2375–2381. doi: 10.1098/rstb.2009.0313
- Armato, U., Bonafini, C., Chakravarthy, B., Pacchiana, R., Chiarini, A., Whitfield, J. F., et al. (2012). The calcium-sensing receptor: a novel Alzheimer's disease crucial target? *J. Neurol. Sci.* 322, 137–140. doi: 10.1016/j.jns.2012.07.031
- Armato, U., Chiarini, A., Chakravarthy, B., Chioffi, F., Pacchiana, R., Colarusso, E., et al. (2013a). Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous A β ₄₂ prompted by exogenous fibrillary or soluble A β ₂₅₋₃₅ in human cortical astrocytes and neurons—Therapeutic relevance to Alzheimer's disease. *Biochim. Biophys. Acta* 1832, 1634–1652. doi: 10.1016/j.bbadis.2013.04.020
- Armato, U., Dal Prà, I., and Chiarini, A. (2013b). *Use of Calcilytic Drugs as a Pharmacological Approach to the Treatment and Prevention of Alzheimer's Disease, Alzheimer's Disease-Related Disorders and Down's Syndrome Neuropathies*. Geneva: WIPO.
- Armstrong, R. A. (2011). Spatial pattern of β amyloid (A β) deposits in familial and sporadic Alzheimer's disease. *Folia Neuropathol.* 49, 153–161.
- Attems, J., Thal, D. R., and Jellinger, K. A. (2012). The relationship between subcortical tau pathology and Alzheimer's disease. *Biochem. Soc. Trans.* 40, 711–715. doi: 10.1042/BST20120034
- Avila-Muñoz, E., and Arias, C. (2014). When astrocytes become harmful: functional and inflammatory responses that contribute to Alzheimer's disease. *Ageing Res. Rev.* 18, 29–40. doi: 10.1016/j.arr.2014.07.004
- Bai, S., Mao, M., Tian, L., Yu, Y., Zeng, J., Ouyang, K., et al. (2015). Calcium sensing receptor mediated the excessive generation of β -amyloid peptide induced by hypoxia *in vivo* and *in vitro*. *Biochem. Biophys. Res. Commun.* 459, 568–573. doi: 10.1016/j.bbrc.2015.02.141
- Bailey, A., Maloney, B., Ge, Y. W., and Lahiri, D. K. (2011). Functional activity of the novel Alzheimer's amyloid β -peptide interacting domain (A β ID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. *Gene* 488, 13–22. doi: 10.1016/j.gene.2011.06.017
- Bandyopadhyay, S., Tfelt-Hansen, J., and Chattopadhyay, N. (2010). Diverse roles of extracellular calcium-sensing receptor in the central nervous system. *J. Neurosci. Res.* 88, 2073–2082. doi: 10.1002/jnr.22391
- Barateiro, A., Brites, D., and Fernandes, A. (2016). Oligodendrocyte development and myelination in neurodevelopment: Molecular mechanisms in health and disease. *Curr. Pharm. Des.* 22, 656–679.
- Barucker, C., Harmeyer, A., Weiske, J., Fauler, B., Albring, K. F., Prokop, S., et al. (2014). Nuclear translocation uncovers the amyloid peptide A β ₄₂ as a regulator of gene transcription. *J. Biol. Chem.* 289, 20182–20191. doi: 10.1074/jbc.M114.564690
- Benzinger, T. L., Blazey, T., Jack, C. R. Jr., Koeppe, R. A., Su, Y., Xiong, C., et al. (2013). Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. *Proc. Natl. Acad. Sci. U.S.A.* 110, E4502–E4509. doi: 10.1073/pnas.1317918110
- Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., et al. (2011). Neuronal activity regulates the regional vulnerability to amyloid- β deposition. *Nat. Neurosci.* 14, 750–756. doi: 10.1038/nn.2801
- Berridge, M. J. (2014). Calcium regulation of neural rhythms, memory and Alzheimer's disease. *J. Physiol.* 592(Pt 2), 281–293. doi: 10.1113/jphysiol.2013.257527
- Bezprozvanny, I., and Mattson, M. P. (2008). Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. *Trends Neurosci.* 31, 454–463. doi: 10.1016/j.tins.2008.06.005
- Bilousova, T., Miller, C. A., Poon, W. W., Vinters, H. V., Corrada, M., Kawas, C., et al. (2016). Synaptic amyloid- β oligomers precede p-Tau and

- differentiate high pathology control cases. *Am. J. Pathol.* 186, 185–198. doi: 10.1016/j.ajpath.2015.09.018
- Bitting, L., Naidu, A., Cordell, B., and Murphy, G. M. Jr. (1996). Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. *J. Biol. Chem.* 271, 16084–16089. doi: 10.1074/jbc.271.27.16084
- Blasko, I., Veerhuis, R., Stampfer-Koutchev, M., Sauerwein-Teissl, M., Eikelenboom, P., and Grubeck-Loebenstein, B. (2000). Costimulatory effects of interferon- γ and interleukin-1 β or tumor necrosis factor- α on the synthesis of A β 1–40 and A β 1–42 by human astrocytes. *Neurobiol. Dis.* 7, 682–689. doi: 10.1006/nbdi.2000.0321
- Bonfanti, L., and Peretto, P. (2007). Radial glial origin of the adult neural stem cells in the subventricular zone. *Prog. Neurobiol.* 83, 24–36. doi: 10.1016/j.pneurobio.2006.11.002
- Bouter, Y., Dietrich, K., Wittnam, J. L., Rezaei-Ghaleh, N., Pillot, T., Papot-Couturier, S., et al. (2013). N-truncated amyloid β (A β)4–42 forms stable aggregates and induces acute and long-lasting behavioral deficits. *Acta Neuropathol.* 126, 189–205. doi: 10.1007/s00401-013-1129-2
- Braak, H., and Braak, E. (1991a). Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* 82, 239–259. doi: 10.1007/BF00308809
- Braak, H., and Braak, E. (1991b). Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. *Brain Pathol.* 1, 213–216. doi: 10.1111/j.1750-3639.1991.tb00661.x
- Braak, H., and Del Tredici, K. (2013). Evolutional aspects of Alzheimer's disease pathogenesis. *J. Alzheimers Dis.* 33, S155–S161. doi: 10.3233/JAD-2012-129029
- Braak, H., Zetterberg, H., Del Tredici, K., and Blennow, K. (2013). Intraneuronal Tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of Tau in cerebrospinal fluid. *J. Alzheimers Dis.* 33, S67–S78. doi: 10.1007/s00401-013-1139-0
- Brandenburg, L. O., Konrad, M., Wruck, C. J., Koch, T., Lucius, R., and Pufe, T. (2010). Functional and physical interactions between formyl-peptide-receptors and scavenger receptor MARCO and their involvement in amyloid β 1–42-induced signal transduction in glial cells. *J. Neurochem.* 113, 749–760. doi: 10.1111/j.1471-4159.2010.06637.x
- Bretschneider, J., Del Tredici, K., Lee, V. M., and Trojanowski, J. Q. (2015). Spreading of pathology in neurodegenerative diseases: a focus on human studies. *Nat. Rev. Neurosci.* 16, 109–120. doi: 10.1038/nrn3887
- Brorson, J. R., Bindokas, V. P., Iwama, T., Marcuccilli, C. J., Chisholm, J. C., and Miller, R. J. (1995). The Ca²⁺ influx induced by beta-amyloid peptide 25–35 in cultured hippocampal neurons results from network excitation. *J. Neurobiol.* 26, 325–338. doi: 10.1002/neu.480260305
- Brunaud, L., Ngueyon Sime, W., Filipozzi, P., Nomine-Criqui, C., Aronova, A., Zarnegar, R., et al. (2016). Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis. *Surgery* 159, 183–192. doi: 10.1016/j.surg.2015.06.058
- Busciglio, J., Gabuzda, D. H., Matsudaira, P., and Yankner, B. A. (1993). Generation of beta-amyloid in the secretory pathway in neuronal and non-neuronal cells. *Proc. Natl. Acad. Sci. U.S.A.* 90, 2092–2096. doi: 10.1073/pnas.90.5.2092
- Bushong, E. A., Martone, M. E., Jones, Y. Z., and Ellisman, M. H. (2002). Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. *J. Neurosci.* 22, 183–192.
- Cai, Z., and Xiao, M. (2016). Oligodendrocytes and Alzheimer's disease. *Int. J. Neurosci.* 126, 97–104. doi: 10.3109/00207454.2015.1025778
- Caillet-Boudin, M.-L., Buée, L., Sergeant, N., and Lefebvre, B. (2015). Regulation of human MAPT gene expression. *Mol. Neurodegen.* 10, 28. doi: 10.1186/s13024-015-0025-8
- Cárdenas-Aguayo, M. d. C., Silva-Lucero, M. d. C., Cortes-Ortiz, M., Jiménez-Ramos, B., Gómez-Virgilio, L., Ramírez-Rodríguez, G., et al. (2014). "Physiological role of amyloid beta in neural cells: the cellular trophic activity," in *Neurochemistry*, ed T. Heinbockel (Rijeka: InTech), 1–25.
- Castellano, J. M., Deane, R., Gottesdiener, A. J., Verghese, P. B., Stewart, F. R., West, T., et al. (2012). Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood A β clearance in a mouse model of β -amyloidosis. *Proc. Natl. Acad. Sci. U.S.A.* 109, 15502–15507. doi: 10.1073/pnas.1206446109
- Chakravarthy, B., Menard, M., Ito, S., Gaudet, C., Dal Prà, I., Armato, U., et al. (2012). Hippocampal membrane-associated p75NTR levels are increased in Alzheimer's disease. *J. Alzheimers Dis.* 30, 675–684. doi: 10.3233/JAD-2012-120115
- Chattopadhyay, N., Espinosa-Jeffrey, A., Tfelt-Hansen, J., Yano, S., Bandyopadhyay, S., Brown, E. M., et al. (2008). Calcium receptor expression and function in oligodendrocyte commitment and lineage progression: potential impact on reduced myelin basic protein in CaR-null mice. *J. Neurosci. Res.* 86, 2159–2167. doi: 10.1002/jnr.21662
- Chattopadhyay, N., Evliyaoglu, C., Heese, O., Carroll, R., Sanders, J., Black, P., et al. (2000). Regulation of secretion of PTHrP by Ca(2+)-sensing receptor in human astrocytes, astrocytomas, and meningiomas. *Am. J. Physiol. Cell Physiol.* 279, C691–C699.
- Chattopadhyay, N., Ye, C., Yamaguchi, T., Nakai, M., Kifor, O., Vassilev, P. M., et al. (1999). The extracellular calcium-sensing receptor is expressed in rat microglia and modulates an outward K⁺ channel. *J. Neurochem.* 72, 1915–1922.
- Chen, W., Bergsman, J. B., Wang, X., Gilkey, G., Pierpoint, C. R., Daniel, E. A., et al. (2010). Presynaptic external calcium signaling involves the calcium-sensing receptor in neocortical nerve terminals. *PLoS ONE* 5:e8563. doi: 10.1371/journal.pone.0008563
- Chen, X. F., Zhang, Y. W., Xu, H., and Bu, G. (2013). Transcriptional regulation and its misregulation in Alzheimer's disease. *Mol. Brain* 6:44. doi: 10.1186/1756-6606-6-44
- Chiarini, A., Dal Prà, I., Menapace, L., Pacchiana, R., Whitfield, J. F., and Armato, U. (2005). Soluble amyloid beta-peptide and myelin basic protein strongly stimulate, alone and in synergism with combined proinflammatory cytokines, the expression of functional nitric oxide synthase-2 in normal adult human astrocytes. *Int. J. Mol. Med.* 16, 801–807.
- Chiarini, A., Whitfield, J. F., Bonafini, C., Chakravarthy, B., Armato, U., and Dal Prà, I. (2010). Amyloid- β (25–35), an amyloid- β (1–42) surrogate, and proinflammatory cytokines stimulate VEGF-A secretion by cultured, early passage, normoxic adult human cerebral astrocytes. *J. Alzheimers Dis.* 21, 915–926. doi: 10.3233/JAD-2010-100471
- Choi, H., Park, H. H., Lee, K. Y., Choi, N. Y., Yu, H. J., Lee, Y. J., et al. (2013). Coenzyme Q10 restores amyloid beta-inhibited proliferation of neural stem cells by activating the PI3K pathway. *Stem Cells Dev.* 22, 2112–2120. doi: 10.1089/scd.2012.0604
- Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D'Avanzo, C., et al. (2014). A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* 515, 274–278. doi: 10.1038/nature13800
- Choo, I. L., Carter, S. F., Schöll, M. L., and Nordberg, A. (2014). Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. *Eur. J. Nucl. Med. Mol. Imaging* 41, 2120–2126. doi: 10.1007/s00259-014-2859-7
- Conley, Y. P., Mukherjee, A., Kammerer, C., DeKosky, S. T., Kamboh, M. I., Finegold, D. N., et al. (2009). Evidence supporting a role for the calcium-sensing receptor in Alzheimer disease. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 150B, 703–709. doi: 10.1002/ajmg.b.30896
- Corbett, G. T., and Buss, E. W. (2014). Non-neuronal cells exacerbate β -amyloid aggregation in the aged brain. *J. Neurosci.* 34, 9825–9827. doi: 10.1523/JNEUROSCI.1825-14.2014
- Crimins, J. L., Pooler, A., Polydorou, M., Luebke, J. I., and Spires-Jones, T. L. (2013). The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. *Ageing Res. Rev.* 12, 757–763. doi: 10.1016/j.arr.2013.03.002
- Cummings, J. L., Morstorf, T., and Zhong, K. (2014). Alzheimer's disease drug-development pipeline: few candidates, frequent failures. *Alzheimers Res. Ther.* 6, 37. doi: 10.1186/alzrt269
- Dal Prà, I., Armato, U., and Chiarini, A. (2015b). "Specific interactions of calcium-sensing receptors (CaSRs) with soluble amyloid- β peptides—A study using cultured cortical normofunctioning adult human astrocytes," in *Proceedings of the 2nd International Symposium on the Calcium-Sensing Receptor* (San Diego, CA), 90–91.
- Dal Prà, I., Armato, U., Chioffi, F., Pacchiana, R., Whitfield, J. F., Chakravarthy, B., et al. (2014b). The A β peptides-activated calcium-sensing receptor stimulates the production and secretion of vascular endothelial growth factor-A by normoxic adult human cortical astrocytes. *Neuromolecular Med.* 16, 645–657. doi: 10.1007/s12017-014-8315-9
- Dal Prà, I., Chiarini, A., Gui, L., Chakravarthy, B., Pacchiana, R., Gardenal, E., et al. (2015a). Do astrocytes collaborate with neurons in spreading the "infectious" A β and Tau drivers of Alzheimer's disease? *Neuroscientist* 21, 9–29. doi: 10.1177/1073858414529828

- Dal Prà, I., Chiarini, A., Nemeth, E. F., Armato, U., and Whitfield, J. F. (2005). Roles of Ca^{2+} and the Ca^{2+} -sensing receptor (CaSR) in the expression of inducible NOS (nitric oxide synthase)-2 and its BH4 (tetrahydrobiopterin)-dependent activation in cytokine-stimulated adult human astrocytes. *J. Cell. Biochem.* 96, 428–438. doi: 10.1002/jcb.20511
- Dal Prà, I., Chiarini, A., Pacchiana, R., Gardenal, E., Chakravarthy, B., Whitfield, J. F., et al. (2014a). Calcium-sensing receptors of human astrocyte-neuron teams: Amyloid- β -driven mediators and therapeutic targets of Alzheimer's Disease. *Curr. Neuropharmacol.* 12, 353–364. doi: 10.2174/1570159X12666140828214701
- Dal Prà, I., Whitfield, J. F., Pacchiana, R., Bonafini, C., Talacchi, A., Chakravarthy, B., et al. (2011). The amyloid- β 42 proxy, amyloid- β 25–35, induces normal human cerebral astrocytes to produce amyloid- β 42. *J. Alzheimers Dis.* 24, 335–347. doi: 10.3233/JAD-2011-101626
- Davey, A. E., Leach, K., Valant, C., Conigrave, A. D., Sexton, P. M., and Christopolous, A. (2012). Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. *Endocrinology* 153, 4304–4316. doi: 10.1210/en.2011-1426
- Derecki, N. C., Cronk, J. C., and Kipnis, J. (2013). The role of microglia in brain maintenance: implications for Rett syndrome. *Trends Immunol.* 34, 144–150. doi: 10.1016/j.it.2012.10.002
- Doens, D., and Fernandez, P. L. (2014). Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis. *J. Neuroinflammation* 11:48. doi: 10.1186/1742-2094-11-48
- Domert, J., Rao, S. B., Agholme, L., Brorsson, A. C., Marcusson, J., Hallbeck, M., et al. (2014). Spreading of amyloid- β peptides via neuritic cell-to-cell transfer is dependent on insufficient cellular clearance. *Neurobiol. Dis.* 65, 82–92. doi: 10.1016/j.nbd.2013.12.019
- Du, H., Li, P., Wang, J., Qing, X., and Li, W. (2012). The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. *Cell. Mol. Neurobiol.* 32, 141–147. doi: 10.1007/s10571-011-9744-8
- Eisele, Y. S., Bolmont, T., Heikenwalder, M., Langer, F., Jacobson, L. H., Yan, Z. X., et al. (2009). Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. *Proc. Natl. Acad. Sci. U.S.A.* 106, 12926–12931. doi: 10.1073/pnas.0903200106
- Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A., Wolburg, H., et al. (2010). Peripherally applied amyloid-beta-containing inoculates induce cerebral beta-amyloidosis. *Science* 330, 980–982. doi: 10.1126/science.1194516
- Färber, K., and Kettenmann, H. (2006). Functional role of calcium signals for microglial function. *Glia* 54, 656–665. doi: 10.1002/glia.20412
- Ferreira, S. T., and Klein, W. L. (2011). The A β oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. *Neurobiol. Learn. Mem.* 96, 529–543. doi: 10.1016/j.nlm.2011.08.003
- Fu, W., Ruangkittisakul, A., MacTavish, D., Shi, J. Y., Ballanyi, K., and Jhamandas, J. H. (2012). Amyloid β (A β) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. *J. Biol. Chem.* 287, 18820–18830. doi: 10.1074/jbc.M111.331181
- García-Osta, A., and Alberini, C. M. (2009). Amyloid beta mediates memory formation. *Learn. Mem.* 16, 267–272. doi: 10.1101/lm.1310209
- Giaume, C., Koulakoff, A., Roux, L., Holcman, D., and Rouach, N. (2010). Astroglial networks: a step further in neuroglial and gliovascular interactions. *Nat. Rev. Neurosci.* 11, 87–99. doi: 10.1038/nrn2757
- Giuffrida, M. L., Tomasello, F., Caraci, F., Chiechio, S., Nicoletti, F., and Copani, A. (2012). Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease. *Mol. Neurobiol.* 46, 605–613. doi: 10.1007/s12035-012-8313-6
- Gómez-Isla, T., Price, J. L., McKeel, D. W. Jr., Morris, J. C., Growdon, J. H., and Hyman, B. T. (1996). Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. *J. Neurosci.* 16, 4491–4500.
- Gundersen, V., Storm-Mathisen, J., and Bergersen, L. H. (2015). Neuroglial transmission. *Physiol. Rev.* 95, 695–726. doi: 10.1152/physrev.00024.2014
- Gunn, A. P., Masters, C. L., and Cherny, R. A. (2010). Pyroglutamate-A β : role in the natural history of Alzheimer's disease. *Int. J. Biochem. Cell. Biol.* 42, 1915–1918. doi: 10.1016/j.biocel.2010.08.015
- Hablitz, J. J., Heinemann, U., and Lux, H. D. (1986). Step reductions in extracellular Ca^{2+} activate a transient inward current in chick dorsal root ganglion cells. *Biophys. J.* 50, 753–757. doi: 10.1016/S0006-3495(86)83515-9
- Halassa, M. M., and Haydon, P. G. (2010). Integrated brain circuits: astrocyte networks modulate neuronal activity and behavior. *Annu. Rev. Physiol.* 72, 335–355. doi: 10.1146/annurev-physiol-021909-135843
- Hallbeck, M., Nath, S., and Marcusson, J. (2013). Neuron-to-neuron transmission of neurodegenerative pathology. *Neuroscientist* 19, 560–566. doi: 10.1177/1073858413494270
- Hamaguchi, T., Eisele, Y. S., Varvei, N. H., Lamb, B. T., Walker, L. C., and Jucker, M. (2012). The presence of amyloid-beta seeds, and not age *per se*, is critical to the initiation of amyloid-beta deposition in the brain. *Acta Neuropathol.* 123, 31–37. doi: 10.1007/s00401-011-0912-1
- Han, F., Wang, W., and Chen, C. (2015). Research progress in animal models and stem cell therapy for Alzheimer's disease. *J. Neurorestorol.* 3, 11–22. doi: 10.2147/JN.S74160
- Han, X., Chen, M., Wang, F., Windrem, M., Wang, S., Shanz, S., et al. (2013). Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. *Cell Stem Cell* 12, 342–353. doi: 10.1016/j.stem.2012.12.015
- Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297, 353–356. Erratum in: *Science* (2002) 297(5590), 2209. doi: 10.1126/science.1072994
- Harry, G. J. (2013). Microglia during development and aging. *Pharmacol. Ther.* 139, 313–326. doi: 10.1016/j.pharmthera.2013.04.013
- Helman, A. M., and Murphy, M. P. (2016). Vascular cognitive impairment: Modeling a critical neurologic disease *in vitro* and *in vivo*. *Biochim. Biophys. Acta.* 1862, 975–982. doi: 10.1016/j.bbadis.2015.12.009
- Hendy, G. N., Canaff, L., and Cole, D. E. (2013). The CASR gene: alternative splicing and transcriptional control, and calcium-sensing receptor (CaSR) protein: structure and ligand binding sites. *Best Pract. Res. Clin. Endocrinol. Metab.* 27, 285–301. doi: 10.1016/j.beem.2013.02.009
- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature* 493, 674–678. doi: 10.1038/nature11729
- Immke, D. C., and McCleskey, E. W. (2001). Lactate enhances the acid-sensing Na⁺ channel on ischemia-sensing neurons. *Nat. Neurosci.* 4, 869–870. doi: 10.1038/nn0901-869
- Iribarren, P., Zhou, Y., Hu, J., Le, Y., and Wang, J. M. (2005). Role of formyl peptide receptor-like 1 (FPR1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. *Immunol. Res.* 31, 165–176. doi: 10.1385/IR:31:3:165
- Irwin, D. J., Abrams, J. Y., Schonberger, L. B., Leschek, E. W., Mills, J. L., Lee, V. M., et al. (2013). Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. *JAMA Neurol.* 70, 462–468. doi: 10.1001/jamaneurol.2013.1933
- Ising, C., Stanley, M., and Holtzman, D. M. (2015). Current thinking on the mechanistic basis of Alzheimer's and implications for drug development. *Clin. Pharmacol. Ther.* 98, 469–471. doi: 10.1002/cpt.200
- Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V., and Hooper, N. M. (2016). Amyloid- β receptors: the good, the bad and the prion protein. *J. Biol. Chem.* 291, 3174–3183. doi: 10.1074/jbc.R115.702704
- Jawhar, S., Wirths, O., and Bayer, T. A. (2011). Pyroglutamate amyloid- β (A β): a hatchet man in Alzheimer disease. *J. Biol. Chem.* 286, 38825–38832. doi: 10.1074/jbc.R111.288308
- John, M. R., Harfst, E., Loeffler, J., Belleli, R., Mason, J., Bruin, G. J., et al. (2014). AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. *Bone* 64, 204–210. doi: 10.1016/j.bone.2014.04.015
- Jurgensen, S., and Ferreira, S. T. (2010). Nicotinic receptors, amyloid beta, and synaptic failure in Alzheimer's disease. *J. Mol. Neurosci.* 40, 221–229. doi: 10.1007/s12031-009-9237-0
- Kam, T. I., Gwon, Y., and Jung, Y. K. (2014). Amyloid beta receptors responsible for neurotoxicity and cellular defects in Alzheimer's disease. *Cell. Mol. Life Sci.* 71, 4803–4813. doi: 10.1007/s00018-014-1706-0
- Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., and Kosenko, E. A. (2010). Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25–35). *Exp. Neurol.* 221, 26–37. doi: 10.1016/j.expneurol.2009.09.005
- Kanekiyo, T., Cirrito, J. R., Liu, C.-C., Shinohara, M., Li, J., Schuler, D. R., et al. (2013). Neuronal clearance of amyloid- β by endocytic receptor LRP1. *J. Neurosci.* 33, 19276–19283. doi: 10.1523/JNEUROSCI.3487-13.2013

- Kanekiyo, T., Liu, C. C., Shinohara, M., Li, J., and Bu, G. (2012). LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid- β . *J. Neurosci.* 32, 16458–16465. doi: 10.1523/JNEUROSCI.3987-12.2012
- Kapur, K., Johnson, T., Beckmann, N. D., Sehmi, J., Tanaka, T., Kutalik, Z., et al. (2010). Genome-wide meta-analysis for serum calcium identifies significantly associated SNPs near the calcium-sensing receptor (CASR) gene. *PLoS Genet* 6:e1001035. doi: 10.1371/journal.pgen.1001035
- Kaufman, A. C., Salazar, S. V., Haas, L. T., Yang, J., Kostylev, M. A., Jeng, A. T., et al. (2015). Fyn inhibition rescues established memory and synapse loss in Alzheimer mice. *Ann. Neurol.* 77, 953–971. doi: 10.1002/ana.24394
- Kawahara, M. (2010). Neurotoxicity of β -amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis. *Curr. Pharm. Des.* 16, 2779–2789. doi: 10.2174/138161210793176545
- Kawanokuchi, J., Mizuno, T., Takeuchi, H., Kato, H., Wang, J., Mitsuma, N., et al. (2006). Production of interferon gamma by microglia. *Mult. Scler.* 12, 558–564. doi: 10.1177/1352458506070763
- Kayed, R., and Lasagna-Reeves, C. A. (2013). Molecular mechanisms of amyloid oligomers toxicity. *J. Alzheimers Dis.* 33(Suppl. 1), S67–S78. doi: 10.3233/JAD-2012-129001
- Kettenmann, H., and Ransom, B. R. (2013). *Neuroglia, 3rd Edn.* New York, NY: Oxford University Press.
- Khan, U. A., Liu, L., Provenzano, F. A., Berman, D. E., Profaci, C. P., Sloan, R., et al. (2014). Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease. *Nat. Neurosci.* 17, 304–311. doi: 10.1038/nn.3606
- Kim, J. Y., Ho, H., Kim, N., Liu, J., Yenari, M. A., and Wenhan, C. (2014). Calcium-sensing receptor (CaSR): a novel target for ischemic neuroprotection. *Ann. Clin. Transl. Neurol.* 1, 851–866. doi: 10.1002/acn3.118
- Kim, W., and Hect, M. H. (2005). Sequence determinants of enhanced amyloidogenicity of Alzheimer A β 42 peptide relative to A β 40. *J. Biol. Chem.* 280, 35069–35076. doi: 10.1074/jbc.M505763200
- Kimbrough, I. F., Robel, S., Roberson, E. D., and Sontheimer, H. (2015). Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. *Brain* 138(Pt 12), 3716–3733. doi: 10.1093/brain/awv327
- Kimura, N., Yanagisawa, K., Terao, K., Ono, F., Sakakibara, I., Ishii, Y., et al. (2005). Age-related changes of intracellular Abeta in Cynomolgus monkey brains. *Neuropathol. Appl. Neurobiol.* 31, 170–180. doi: 10.1111/j.1365-2990.2004.00624.x
- Klein, W. L. (2013). Synaptotoxic amyloid- β oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? *J. Alzheimers Dis.* 33, S49–S65. doi: 10.3233/JAD-2012-129039
- Klemm, W. R. (2014). *Mental Biology: The New Science of How the Brain and Mind Relate.* Amherst, NY: Prometheus Books.
- Koudinov, A. R., and Berezov, T. T. (2004). Alzheimer's amyloid-beta (A β) is an essential synaptic protein, not neurotoxic junk. *Acta Neurobiol. Exp. (Wars)* 64, 71–79.
- Kuchibhotla, K. V., Lattarulo, C. R., Hyman, B. T., and Bacskai, B. J. (2009). Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. *Science* 323, 1211–1215. doi: 10.1126/science.1169096
- Kumar, A., Paslay, L. C., Lyons, D., Morgan, S. E., Correia, J. J., and Rangachari, V. (2012). Specific soluble oligomers of amyloid- β peptide undergo replication and form non-fibrillar aggregates in interfacial environments. *J. Biol. Chem.* 287, 21253–21264. doi: 10.1074/jbc.M112.355156
- Kumar, S., Singh, S., Hinze, D., Josten, M., Sahl, H. G., Siepmann, M., et al. (2012). Phosphorylation of amyloid- β peptide at serine 8 attenuates its clearance via insulin-degrading and angiotensin-converting enzymes. *J. Biol. Chem.* 287, 8641–8651. doi: 10.1074/jbc.M111.279133
- Kumar, S., and Walter, J. (2011). Phosphorylation of amyloid beta (A β) peptides—a trigger for formation of toxic aggregates in Alzheimer's disease. *Aging (Albany NY)* 3, 803–812. doi: 10.18632/aging.100362
- Langer, F., Eisele, Y. S., Fritsch, S. K., Staufienbiel, M., Walker, L. C., and Jucker, M. (2011). Soluble amyloid-beta seeds are potent inducers of cerebral beta-amyloid deposition. *J. Neurosci.* 31, 14488–14495. doi: 10.1523/JNEUROSCI.3088-11.2011
- Leach, K., Conigrave, A. D., Sexton, P. M., and Christopoulos, A. (2015). Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias. *Trends Pharmacol. Sci.* 36, 215–225. doi: 10.1016/j.tips.2015.02.004
- Lee, I. S., Jung, K., Kim, I. S., and Park, K. I. (2013). Amyloid- β oligomers regulate the properties of human neural stem cells through GSK-3 β signaling. *Exp. Mol. Med.* 45, e60. doi: 10.1038/emmm.2013.125
- Lee, L., Kosuri, P., and Arancio, O. (2014). Picomolar amyloid- β peptides enhance spontaneous astrocyte calcium transients. *J. Alzheimers Dis.* 38, 49–62. doi: 10.3233/JAD-130740
- Lee, M., McGeer, E. G., and McGeer, P. L. (2011). Mechanisms of GABA release from human astrocytes. *Glia* 59, 1600–1611. doi: 10.1002/glia.21202
- Lesnè, S. E., Sherman, M. A., Grant, M., Kuskowski, M., Schneider, J. A., Bennett, D. A., et al. (2013). Brain amyloid- β oligomers in ageing and Alzheimer's disease. *Brain* 136, 1383–1398. doi: 10.1093/brain/awt062
- Letz, S., Rus, R., Haag, C., Dörr, H. G., Schnabel, D., Möhlig, M., et al. (2010). Novel activating mutations of the calcium-sensing receptor: the calcilytic NPS-2143 mitigates excessive signal transduction of mutant receptors. *J. Clin. Endocrinol. Metab.* 95, E229–E233. doi: 10.1210/jc.2010-0651
- Li, C., Zhao, R., Gao, K., Wei, Z., Yin, M. Y., Lau, L. T., et al. (2011). Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. *Curr. Alzheimer Res.* 8, 67–80. doi: 10.2174/156720511794604543
- Licht, T., and Keshet, E. (2015). The vascular niche in adult neurogenesis. *Mech. Dev.* 138(Pt 1), 56–62. doi: 10.1016/j.mod.2015.06.001
- Lindberg, C., Selenica, M. L., Westlind-Danielsson, A., and Schultzberg, M. (2005). Beta-amyloid protein structure determines the nature of cytokine release from rat microglia. *J. Mol. Neurosci.* 27, 1–12. doi: 10.1385/JMN:27:1:001
- Liu, C. C., Kanekiyo, T., Xu, H., and Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat. Rev. Neurol.* 9, 106–118. doi: 10.1038/nrneuro.2012.263
- López Salom, M., Pasquini, L., Besio Moreno, M., Pasquini, J. M., and Soto, E. (2003). Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. *Exp. Neurol.* 180, 131–143. doi: 10.1016/S0014-4886(02)00060-2
- Love, S., and Miners, J. S. (2015). Cerebrovascular disease in ageing and Alzheimer's disease. *Acta Neuropathol.* doi: 10.1007/s00401-015-1522-0. [Epub ahead of print].
- Lu, B., Zhang, Q., Wang, H., Wang, Y., Nakayama, M., and Ren, D. (2010). Extracellular calcium controls background current and neuronal excitability via an UNC79-UNC80-NALCN cation channel complex. *Neuron* 68, 488–499. doi: 10.1016/j.neuron.2010.09.014
- Ma, Z., Siebert, A. P., Cheung, K. H., Lee, R. J., Johnson, B., Cohen, A. S., et al. (2012). Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca $^{2+}$ regulation of neuronal excitability. *Proc. Natl. Acad. Sci. U.S.A.* 109, E1963–E1971. doi: 10.1073/pnas.1204023109
- Macleod, C. J., Baker, H. F., Ridley, R. M., and Mori, H. (2000). Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (*Callithrix jacchus*). *J. Neural. Transm.* 107, 799–814. doi: 10.1007/s007020070060
- Magdesian, M. H., Carvalho, M. M., Mendes, F. A., Saraiva, L. M., Juliano, M. A., Juliano, L., et al. (2008). Amyloid-beta binds to the extracellular cysteine-rich domain of frizzled and inhibits Wnt/beta-catenin signaling. *J. Biol. Chem.* 283, 9359–9368. doi: 10.1074/jbc.M707108200
- Maloney, B., and Lahiri, D. K. (2011). The Alzheimer's amyloid β -peptide (A β) binds a specific DNA A β -interacting domain (A β ID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: Characterizing a new regulatory motif. *Gene* 488, 1–12. doi: 10.1016/j.gene.2011.06.004
- Mandrekar-Colucci, S., and Landreth, G. E. (2010). Microglia and inflammation in Alzheimer's disease. *CNS Neurol. Disord. Drug Targets* 9, 156–167. doi: 10.2174/187152710791012071
- Mao, P., and Reddy, P. H. (2011). Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics. *Biochim. Biophys. Acta* 1812, 1359–1370. doi: 10.1016/j.bbdis.2011.08.005
- Maragakis, N. J., and Rothstein, J. D. (2006). Mechanisms of disease: astrocytes in neurodegenerative disease. *Nat. Clin. Pract. Neurol.* 2, 679–689. doi: 10.1038/ncpneuro0355
- Marsden, I. T., Minamide, L. S., and Bamberg, J. R. (2011). Amyloid- β -induced amyloid- β secretion: a possible feed-forward mechanism in

- Alzheimer's Disease. *J. Alzheimer's Dis.* 24, 681–691. doi: 10.3233/JAD-2011-101899
- Massy, Z. A., Hénaut, L., Larsson, T. E., and Vervloet, M. G. (2014). Calcium-sensing receptor activation in chronic kidney disease: effects beyond parathyroid hormone control. *Semin. Nephrol.* 34, 648–659. doi: 10.1016/j.semnephrol.2014.10.001
- Masters, C. L., and Selkoe, D. J. (2012). "Biochemistry of amyloid- β protein and amyloid deposits in Alzheimer disease," in *The Biology of Alzheimer's Disease*, eds D. J. Selkoe, E. Mandelkow, and D. M. Holtzman (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press), 181–204.
- Mattson, M. P. (2007). Calcium and neurodegeneration. *Aging Cell* 6, 337–350. doi: 10.1111/j.1474-9726.2007.00275.x
- Mattson, M. P., and Chan, S. L. (2003). Neuronal and glial calcium signaling in Alzheimer's disease. *Cell Calcium* 34, 385–397. doi: 10.1016/S0143-4160(03)00128-3
- Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* 330, 1774. doi: 10.1126/science.1197623
- Mayr, B. M., Schnabel, D., Dörr, H. G., and Schöfl, C. (2016). Genetics in Endocrinology: gain and loss of function mutations of the Calcium Sensing Receptor and associated proteins: Current treatment concepts. *Eur. J. Endocrinol.* 174, R189–R208. doi: 10.1530/EJE-15-1028
- McGeer, P. L., and McGeer, E. G. (2015). Targeting microglia for the treatment of Alzheimer's disease. *Expert Opin. Ther. Targets* 19, 497–506. doi: 10.1517/14728222.2014.988707
- Medeiros, R., Chabrier, M. A., and LaFerla, F. M. (2013). Elucidating the triggers, progression, and effects of Alzheimer's disease. *J. Alzheimers Dis.* 33(Suppl. 1), S195–S210. doi: 10.3233/JAD-2012-12900
- Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., et al. (2006). Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. *Science* 313, 1781–1784. doi: 10.1126/science.1131864
- Miller, G., Davis, J., Shatzen, E., Colloton, M., Martin, D., and Henley, C. M. (2012). Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. *Nephrol. Dial. Transplant.* 27, 2198–2205. doi: 10.1093/ndt/gfr589
- Mizuno, T. (2012). The biphasic role of microglia in Alzheimer's disease. *Int. J. Alzheimers Dis.* 2012:737846. doi: 10.1155/2012/737846
- Morales, R., Callegari, K., and Soto, C. (2015). Prion-like features of misfolded A β and tau aggregates. *Virus Res.* 207, 106–112. doi: 10.1016/j.virusres.2014.12.031
- Morawski, M., Schilling, S., Kreuzberger, M., Waniek, A., Jäger, C., Koch, B., et al. (2014). Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid- β load and cognitive decline in Alzheimer's disease. *J. Alzheimers Dis.* 39, 385–400. doi: 10.3233/JAD-131535
- Moreno-Gonzalez, I., and Soto, C. (2011). Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. *Semin. Cell Dev. Biol.* 22, 482–487. doi: 10.1016/j.semdb.2011.04.002
- Morley, J. E., Farr, S. A., Banks, W. A., Johnson, S. N., Yamada, K. A., and Xu, L. (2010). A physiological role for amyloid-beta protein: enhancement of learning and memory. *J. Alzheimers Dis.* 19, 441–449. doi: 10.3233/JAD-2009-1230
- Morrison, J. H., and Hof, P. R. (2007). Life and death of neurons in the aging cerebral cortex. *Int. Rev. Neurobiol.* 81, 41–57. doi: 10.1016/S0074-7742(06)81004-4
- Mulder, S. D., Veerhuis, R., Blankenstein, M. A., and Nielsen, H. M. (2012). The effect of amyloid associated proteins on the expression of genes involved in amyloid- β clearance by adult human astrocytes. *Exp. Neurol.* 233, 373–379. doi: 10.1016/j.expneurol.2011.11.001
- Müller, M., Cheung, K. H., and Foskett, J. K. (2011). Enhanced ROS generation mediated by Alzheimer's disease presenilin regulation of InsP3R Ca²⁺ signaling. *Antioxid. Redox Signal.* 14, 1225–1235. doi: 10.1089/ars.2010.3421
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., et al. (2015). Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. *Brain* 138, 1370–1381. doi: 10.1093/brain/awv050
- Nagele, R. G., Wegiel, J., Venkataraman, V., Imaki, H., Wang, K. C., and Wegiel, J. (2004). Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. *Neurobiol. Aging* 25, 663–674. doi: 10.1016/j.neurobiolaging.2004.01.007
- Nath, S., Agholme, L., Kurudenkandy, F. R., Granseth, B., Marcusson, J., and Hallbeck, M. (2012). Spreading of neurodegenerative pathology via neuron-to-neuron transmission of β -amyloid. *J. Neurosci.* 32, 8767–8777. doi: 10.1523/JNEUROSCI.0615-12.2012
- Nelson, A. R., Sweeney, M. D., Sagare, A. P., and Zlokovic, B. V. (2016). Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease. *Biochim. Biophys. Acta* 1862, 887–900. doi: 10.1016/j.bbadis.2015.12.016
- Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., et al. (2012). Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. *J. Neuropathol. Exp. Neurol.* 71, 362–381. doi: 10.1097/NEN.0b013e31825018f7
- Nemeth, E. F. (2002). The search for calcium receptor antagonists (calcilytics). *J. Mol. Endocrinol.* 29, 15–21. doi: 10.1677/jme.0.0290015
- Nemeth, E. F. (2004). Calcimimetic and calcilytic drugs: just for parathyroid cells? *Cell Calcium* 35, 283–289. doi: 10.1016/j.ceca.2003.10.020
- Nemeth, E. F. (2013). Allosteric modulators of the extracellular calcium receptor. *Drug Discov. Today Technol.* 10, e277–e284. doi: 10.1016/j.ddtec.2012.11.002
- Nemeth, E. F. (2015). "The calcium receptors as a therapeutic target," in *Proceedings of the 2nd International Symposium on the Calcium-sensing Receptor* (San Diego, CA) March 3-4; USA. Abstract Book, 41, OR-036.
- Nemeth, E. F., and Goodman, W. G. (2015). Calcimimetic and calcilytic drugs: feats, flops, and futures. *Calcif. Tissue Int.* 98, 341–358. doi: 10.1007/s00223-015-0052-z
- Nemeth, E. F., and Shoback, D. (2013). Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders. *Best Pract. Res. Clin. Endocrinol. Metab.* 27, 373–384. doi: 10.1016/j.beem.2013.02.008
- Nimmrich, V., Grimm, C., Draguhn, A., Barghorn, S., Lehmann, A., Schoemaker, H., et al. (2008). Amyloid β oligomers (A β (1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. *J. Neurosci.* 28, 788–797. doi: 10.1523/JNEUROSCI.4771-07.2008
- Noh, J. S., Pak, H. J., Shin, Y. J., Riew, T. R., Park, J. H., Moon, Y. W., et al. (2015). Differential expression of the calcium-sensing receptor in the ischemic and border zones after transient focal cerebral ischemia in rats. *J. Chem. Neuroanat.* 66–67, 40–51. doi: 10.1016/j.jchemneu.2015.05.001
- Nordberg, A. (2014). "Astroglia and microglia imaging markers in the progression of Alzheimer's disease," in *13th Intl. Geneva/Springfield Symposium on Advances in Alzheimer Therapy*. Abstract Book (Geneva), 65.
- Nordberg, A. (2015). Dementia in 2014. Towards early diagnosis in Alzheimer disease. *Nat. Rev. Neurol.* 11, 69–70. doi: 10.1038/nrneuro.2014.257
- Nussbaum, J. M., Seward, M. E., and Bloom, G. S. (2013). Alzheimer disease: a tale of two prions. *Prion* 7, 14–19. doi: 10.4161/pri.22118
- Nygaard, H. B., and Strittmatter, S. M. (2009). Cellular prion protein mediates the toxicity of β -Amyloid oligomers. Implications for Alzheimer Disease. *Arch. Neurol.* 66, 1325–1328. doi: 10.1001/archneurol.2009.223
- Oberheim, N. A., Goldman, S. A., and Nedergaard, M. (2012). Heterogeneity of astrocytic form and function. *Methods Mol. Biol.* 814, 23–45. doi: 10.1007/978-1-61779-452-0_3
- Oberheim, N. A., Takano, T., Han, X., He, W., Lin, J. H., Wang, F., et al. (2009). Uniquely hominid features of adult human astrocytes. *J. Neurosci.* 29, 3276–3287. doi: 10.1523/JNEUROSCI.4707-08.2009
- Oberheim, N. A., Wang, X., Goldman, S., and Nedergaard, M. (2006). Astrocytic complexity distinguishes the human brain. *Trends Neurosci.* 29, 547–553. doi: 10.1016/j.tins.2006.08.004
- Oberstein, T. J., Spitzer, P., Klafki, H. W., Linning, P., Neff, F., Knölker, H. J., et al. (2015). Astrocytes and microglia but not neurons preferentially generate N-terminally truncated A β peptides. *Neurobiol. Dis.* 73, 24–35. doi: 10.1016/j.nbd.2014.08.031
- Palmer, S. C., Nistor, I., Craig, J. C., Pellegrini, F., Messa, P., Tonelli, M., et al. (2013). Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. *PLoS Med.* 10:e1001436 doi: 10.1371/journal.pmed.1001436
- Park, S. Y., Mun, H. C., Eom, Y. S., Baek, H. L., Jung, T. S., Kim, C. H., et al. (2013). Identification and characterization of D410E, a novel mutation in the loop 3 domain of CASR, in autosomal dominant hypocalcemia and a therapeutic approach using a novel calcilytic, AXT914. *Clin. Endocrinol. (Oxf.)* 78, 687–693. doi: 10.1111/cen.12056

- Perez, J. L., Carrero, I., Gonzalo, P., Arevalo-Serrano, J., Sanz-Anquela, J. M., Ortega, J., et al. (2010). Soluble oligomeric forms of beta-amyloid (A β) peptide stimulate A β production via astroglialosis in the rat brain. *Exp. Neurol.* 223, 410–421. doi: 10.1016/j.expneurol.2009.10.013
- Perini, G., Della Bianca, V., Politi, V., Della Valle, G., Dal Prà, I., Rossi, F., et al. (2002). Role of p75 neurotrophin receptor in the neurotoxicity by beta amyloid peptides and synergistic effect of inflammatory cytokines. *J. Exp. Med.* 195, 907–918. Erratum in: (2002). *J. Exp. Med.* 195, (1231). doi: 10.1084/jem.20011797
- Petrel, C., Kessler, A., Dauban, P., Dodd, R. H., Rognan, D., and Ruat, M. (2004). Positive and negative allosteric modulators of the Ca²⁺-sensing receptor interact within overlapping but not identical binding sites in the transmembrane domain. *J. Biol. Chem.* 279, 18990–18997. doi: 10.1074/jbc.M400724200
- Pflanzner, T., Petsch, B., Andre-Dohmen, B., Muller-Schiffmann, A., Tschickardt, S., Weggen, S., et al. (2012). Cellular prion protein participates in amyloid- β transcytosis across the blood-brain barrier. *J. Cereb. Blood Flow Metab.* 32, 628–632. doi: 10.1038/jcbfm.2012.7
- Pihlaja, R., Koistinaho, J., Malm, T., Sikkilä, H., Vainio, S., and Koistinaho, M. (2008). Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. *Glia* 56, 154–163. doi: 10.1002/glia.20599
- Plant, L. D., Boyle, J. P., Smith, I. F., Peers, C., and Pearson, H. A. (2003). The production of amyloid beta peptide is a critical requirement for the viability of central neurons. *J. Neurosci.* 23, 5531–5535.
- Prokop, S., Miller, K. R., and Heppner, F. L. (2013). Microglia actions in Alzheimer's disease. *Acta Neuropathol.* 126, 461–477. doi: 10.1007/s00401-013-1182-x
- Puzzo, D., Privitera, L., Fa, M., Staniszewski, A., Hashimoto, G., Aziz, F., et al. (2011). Endogenous amyloid- β is necessary for hippocampal synaptic plasticity and memory. *Ann. Neurol.* 69, 819–830. doi: 10.1002/ana.22313
- Puzzo, D., Privitera, L., Leznik, E., Fà, M., Staniszewski, A., Palmeri, A., et al. (2008). Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. *J. Neurosci.* 28, 14537–14545. doi: 10.1523/JNEUROSCI.2692-08.2008
- Riccardi, D., and Kemp, P. J. (2012). The calcium-sensing receptor beyond extracellular calcium homeostasis: conception, development, adult physiology, ad disease. *Annu. Rev. Physiol.* 74, 271–297. doi: 10.1146/annurev-physiol-020911-153318
- Rodriguez-Vieitez, E., Ni, R., Gulyás, B., Tóth, M., Häggkvist, J., Halldin, C., et al. (2015). Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and *in vitro* imaging study. *Eur. J. Nucl. Med. Mol. Imaging* 42, 1119–1132. doi: 10.1007/s00259-015-3047-0
- Rojo, L. E., Fernández, J. A., Maccioni, A. A., Jimenez, J. M., and Maccioni, R. B. (2008). Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. *Arch. Med. Res.* 39, 1–16. doi: 10.1016/j.arcmed.2007.10.001
- Rosen, R. F., Fritz, J. J., Dooyema, J., Cintron, A. F., Hamaguchi, T., Lah, J. J., et al. (2012). Exogenous seeding of cerebral beta-amyloid deposition in β APP transgenic rats. *J. Neurochem.* 120, 660–666. doi: 10.1111/j.1471-4159.2011.07551.x
- Rossner, S., Lange-Dohna, C., Zeitschel, U., and Perez-Polo, J. R. (2005). Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme. *J. Neurochem.* 92, 226–234. doi: 10.1111/j.1471-4159.2004.02857.x
- Roth, A. D., Ramírez, G., Alarcón, R., and Von Bernhardi, R. (2005). Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. *Biol. Res.* 38, 381–387. doi: 10.4067/S0716-97602005000400011
- Ruat, M., and Traiffort, E. (2013). Roles of the calcium sensing receptor in the central nervous system. *Best Pract. Res. Clin. Endocrinol. Metab.* 27, 429–442. doi: 10.1016/j.beem.2013.03.001
- Saidak, Z., Brazier, M., Kamel, S., and Mentaverri, R. (2009). Agonists and modulators of the calcium-sensing receptor and their therapeutic applications. *Mol. Pharmacol.* 76, 1131–1144. doi: 10.1124/mol.109.058784
- Saijo, K., and Glass, C. K. (2011). Microglial cell origin and phenotypes in health and disease. *Nat. Rev. Immunol.* 11, 775–787. doi: 10.1038/nri3086
- Sandebring, A., Welander, H., Winblad, B., Graff, C., and Tjernberg, L. O. (2013). The pathogenic A β 43 is enriched in familial and sporadic Alzheimer disease. *PLoS ONE* 8:e55847. doi: 10.1371/journal.pone.0055847
- Santpere, G., Nieto, M., Puig, B., and Ferrer, I. (2006). Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. *Neurosci. Lett.* 397, 30–34. doi: 10.1016/j.neulet.2005.11.062
- Selkoe, D. J. (2008a). Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. *Handb. Clin. Neurol.* 89, 245–260. doi: 10.1016/S0072-9752(07)01223-7
- Selkoe, D. J. (2008b). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. *Behav. Brain Res.* 192, 106–113. doi: 10.1016/j.bbr.2008.02.016
- Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural oligomers of the Alzheimer amyloid-beta protein reversibly synapse loss by modulating an NMDA-type glutamate receptor dependent signaling pathway. *J. Neurosci.* 27, 2866–28675. doi: 10.1523/JNEUROSCI.4970-06.2007
- Sherwood, C. C., Stimpson, C. D., Raghanti, M. A., Wildman, D. E., Uddin, M., Grossman, L. I., et al. (2006). Evolution of increased glia-neuron ratios in the human frontal cortex. *Proc. Natl. Acad. Sci. U.S.A.* 103, 13606–13611. doi: 10.1073/pnas.0605843103
- Shibata, M. (2000). Clearance of Alzheimer's amyloid- β 1-40 peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J. Clin. Invest.* 106, 1489–1499. doi: 10.1172/JCI10498
- Silve, C., Petrel, C., Leroy, C., Bruel, H., Mallet, E., Rognan, D., et al. (2005). Delineating a Ca²⁺ binding pocket within the Venus flytrap module of the human calcium sensing receptor. *J. Biol. Chem.* 280, 37917–37923. doi: 10.1074/jbc.M506263200
- Skaper, S. D., Evans, N. A., Soden, P. E., Rosin, C., Facci, L., and Richardson, J. C. (2009). Oligodendrocytes are a novel source of amyloid peptide generation. *Neurochem. Res.* 34, 2243–2250. doi: 10.1007/s11064-009-0022-9
- Smith, S. M., Bergsman, J. B., Harata, N. C., Scheller, R. H., and Tsien, R. W. (2004). Recordings from single neocortical nerve terminals reveal a nonselective cation channel activated by decreases in extracellular calcium. *Neuron* 41, 243–256. doi: 10.1016/S0896-6273(03)00837-7
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 7, 280–292. doi: 10.1016/j.jalz.2011.03.003
- Stewart, C. R., Stuart, L. M., Wilkinson, K., van Gils, J. M., Deng, J., Halle, A., et al. (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. *Nat. Immunol.* 11, 155–161. doi: 10.1038/ni.1836
- Storck, S. E., Meister, S., Nahrath, J., Meißner, J. N., Schubert, N., Di Spiezio, A., et al. (2016). Endothelial LRP1 transports amyloid- β 1-42 across the blood-brain barrier. *J. Clin. Invest.* 126, 123–136. doi: 10.1172/JCI81108
- Swerdlow, R. H. (2011). Brain aging, Alzheimer's disease, and mitochondria. *Biochim. Biophys. Acta* 1812, 1630–1639. doi: 10.1016/j.bbadis.2011.08.012
- Takami, M., and Funamoto, S. (2012). γ -secretase-dependent proteolysis of transmembrane domain of amyloid precursor protein: successive tri- and tetrapeptide release in amyloid β -protein production. *Int. J. Alzheimers Dis.* 2012:591392. doi: 10.1155/2012/591392
- Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., et al. (2013). A β induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. U.S.A.* 110, E2518–E2527. Correction in: *Proc. Natl. Acad. Sci. U.S.A.* 110, 13691. doi: 10.1073/pnas.1313546110
- Tarasoff-Conway, J. M., Carare, R. O., Osorio, R. S., Glodzik, L., Butler, T., Fieremans, E., et al. (2015). Clearance systems in the brain-implications for Alzheimer disease. *Nat. Rev. Neurol.* 11, 457–470. doi: 10.1038/nrneuro.2015.119
- Tharmalingam, S., Wu, C., and Hampson, D. R. (2016). The calcium-sensing receptor and integrins modulate cerebellar granule cell precursor differentiation and migration. *Dev. Neurobiol.* 6, 375–389. doi: 10.1002/dneu.22321
- Theuns, J., and Van Broeckhoven, C. (2000). Transcriptional regulation of Alzheimer's disease genes: implications for susceptibility. *Hum. Mol. Genet.* 9, 2383–2394. doi: 10.1093/hmg/9.16.2383

- Tsai, H. H., Li, H., Fuentealba, L. C., Molofsky, A. V., Taveira-Marques, R., Zhuang, H., et al. (2012). Regional astrocyte allocation regulates CNS synaptogenesis and repair. *Science* 337, 358–363. doi: 10.1126/science.1222381
- Ullian, E. M., Sapperstein, S. K., Christopherson, K. S., and Barres, B. A. (2001). Control of synapse number by glia. *Science* 291, 657–661. doi: 10.1126/science.291.5504.657
- Vizard, T. N., O'Keefe, G. W., Gutierrez, H., Kos, C. H., Riccardi, D., and Davies, A. M. (2008). Regulation of axonal and dendritic growth by the extracellular calcium-sensing receptor. *Nat Neurosci.* 11, 285–291. doi: 10.1038/nn2044
- Wang, D. S., Dickson, D. W., and Malter, J. S. (2006). Beta-amyloid degradation and Alzheimer's disease. *J. Biomed. Biotechnol.* 2006:58406. doi: 10.1155/JBB/2006/58406
- Wang, G., Dinkins, M., He, Q., Zhu, G., Poirier, C., Campbell, A., et al. (2012). Astrocytes secrete exosomes enriched with pro-apoptosis response 4 (PAR-4): a potential mechanism of apoptosis induction in Alzheimer's disease (AD). *J. Biol. Chem.* 287, 21384–21395. doi: 10.1074/jbc.M112.340513
- Wang, H. Y., Lee, D. H., D'Andrea, M. R., Peterson, P. A., Shank, R. P., and Reitz, A. B. (2000). B Amyloid(1-42) binds to $\alpha 7$ nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. *J. Biol. Chem.* 275, 5626–5632.
- Ward, B. K., Magno, A. L., Walsh, J. P., and Ratajczak, T. (2012). The role of the calcium-sensing receptor in human disease. *Clin. Biochem.* 45, 943–953. doi: 10.1016/j.clinbiochem.2012.03.034
- Wen, Y., Yu, W. H., Maloney, B., Bailey, J., Ma, J., Marié, I., et al. (2008). Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. *Neuron* 57, 680–690. doi: 10.1016/j.neuron.2008.02.024
- West, M. J., Kawas, C. H., Stewart, W. F., Rudow, G. L., and Troncoso, J. C. (2004). Hippocampal neurons in pre-clinical Alzheimer's disease. *Neurobiol. Aging* 25, 1205–1212. doi: 10.1016/j.neurobiolaging.2003.12.005
- White, E., McKenna, J., Cavanaugh, A., and Breitwieser, G. E. (2009). Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-of-function mutants. *Mol. Endocrinol.* 23, 1115–1123. doi: 10.1210/me.2009-0041
- Widler, L. (2011). Calcilytics: antagonists of the calcium-sensing receptor for the treatment of osteoporosis. *Future Med. Chem.* 3, 535–547. doi: 10.4155/fmc.11.17
- Wilkinson, K., and El Khoury, J. (2012). Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. *Int. J. Alzheimers Dis.* 2012:489456. doi: 10.1155/2012/489456
- Wyss-Coray, T., Loike, J. D., Brionne, T. C., Lu, E., Anankov, R., Yan, F., et al. (2003). Adult mouse astrocytes degrade amyloid-beta *in vitro* and *in situ*. *Nat. Med.* 9, 453–457. doi: 10.1038/nm838
- Xiong, Z., Lu, W., and MacDonald, J. F. (1997). Extracellular calcium sensed by a novel cation channel in hippocampal neurons. *Proc. Natl. Acad. Sci. U.S.A.* 94, 7012–7017. doi: 10.1073/pnas.94.13.7012
- Yamamura, A., Guo, Q., Yamamura, H., Zimnicka, A. M., Pohl, N. M., Smith, K. A., et al. (2012). Enhanced Ca²⁺-sensing receptor function in idiopathic pulmonary arterial hypertension. *Circ. Res.* 111, 469–481. doi: 10.1161/CIRCRESAHA.112.266361
- Yamamura, A., Ohara, N., and Tsukamoto, K. (2015). Inhibition of excessive cell proliferation by calcilytics in idiopathic arterial hypertension. *PLoS ONE* 10:e0138384. doi: 10.1371/journal.pone.0138384
- Yang, I., Han, S. J., Kaur, G., Crane, C., and Parsa, A. T. (2010). The role of microglia in central nervous system immunity and glioma immunology. *J. Clin. Neurosci.* 17, 6–10. doi: 10.1016/j.jocn.2009.05.006
- Yano, S., Brown, E. M., and Chattopadhyay, N. (2004). Calcium-sensing receptor in the brain. *Cell Calcium* 35, 257–264. doi: 10.1016/j.ceca.2003.10.008
- Yarova, P. L., Stewart, A., Sathish, V., Britt, R. D. Jr., Thompson, M. A., Lowe, A. P. P., et al. (2015). “Calcilytics as novel therapeutic for treating asthma,” in *Proceedings of the 2nd International Symposium on the Calcium-sensing Receptor*, (San Diego, CA). March 3–4. Abstract Book, pp. 42–43, OR-037.
- Ye, C., Ho-Pao, C. L., Kanazirska, M., Quinn, S., Rogers, K., Seidman, C. E., et al. (1997). Amyloid- β proteins activate Ca²⁺-permeable channels through calcium-sensing receptors. *J. Neurosci. Res.* 47, 547–554.
- Ye, C., Kanazirska, M., Quinn, S., Brown, E. M., and Vassilev, P. M. (1996a). Modulation by polycationic Ca(2+)-sensing receptor agonists of nonselective cation channels in rat hippocampal neurons. *Biochem. Biophys. Res. Commun.* 224, 271–280.
- Ye, C., Rogers, K., Bai, M., Quinn, S. J., Brown, E. M., and Vassilev, P. M. (1996b). Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. *Biochem. Biophys. Res. Commun.* 226, 572–579.
- Zhang, C., Miller, C. L., Brown, E. M., and Yang, J. J. (2015). The calcium sensing receptor: from calcium sensing to signaling. *Sci. China Life Sci.* 58, 14–27. doi: 10.1007/s11427-014-4779-y
- Zhang, Y., Sloan, S. A., Clarke, L. E., Caneda, C., Plaza, C. A., Blumenthal, P. D., et al. (2016). Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with mouse. *Neuron* 89, 37–53. doi: 10.1016/j.neuron.2015.11.013
- Zhao, J., O'Connor, T., and Vassar, R. (2011). The contribution of activated astrocytes to A β production: implications for Alzheimer's disease pathogenesis. *J. Neuroinflammation* 8:150. doi: 10.1186/1742-2094-8-150
- Zhao, L. N., Long, H., Mu, Y., and Chew, L. Y. (2012). The toxicity of amyloid β oligomers. *Int. J. Mol. Sci.* 13, 7303–7327. doi: 10.3390/ijms13067303
- Zhao, W. Q., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., et al. (2008). Amyloid beta oligomers induce impairment of neuronal insulin receptors. *FASEB J.* 22, 246–260. doi: 10.1096/fj.06-7703com
- Zhao, W. Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., et al. (2010). Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid β oligomer-induced synaptic disruption. *J. Biol. Chem.* 285, 7619–7632. doi: 10.1074/jbc.M109.057182
- Ziegelstein, R. C., Xiong, Y., He, C., and Hu, Q. (2006). Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. *Biochem. Biophys. Res. Commun.* 342, 153–163. doi: 10.1016/j.bbrc.2006.01.135

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Chiarini, Armato, Liu and Dal Prà. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.